<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:758.1pt;left:550.0pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">1</span></b></p>
<p style="top:759.7pt;left:181.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lalu&#xa0;M, </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. </span><i><span style="font-family:Arial,serif;font-size:8.0pt">BMJ Open</span></i><span style="font-family:Arial,serif;font-size:8.0pt"> 2019;</span><b><span style="font-family:Arial,serif;font-size:8.0pt">9</span></b><span style="font-family:Arial,serif;font-size:8.0pt">:e029475. doi:10.1136/bmjopen-2019-029475</span></p>
<p style="top:25.1pt;left:44.3pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#ffffff">Open access </span></b></p>
<p style="top:46.9pt;left:146.9pt;line-height:22.0pt"><b><span style="font-family:BookAntiqua,serif;font-size:22.0pt;color:#414099">Mapping the preclinical to clinical </span></b></p>
<p style="top:72.9pt;left:146.9pt;line-height:22.0pt"><b><span style="font-family:BookAntiqua,serif;font-size:22.0pt;color:#414099">evidence and development trajectory of </span></b></p>
<p style="top:98.9pt;left:146.9pt;line-height:22.0pt"><b><span style="font-family:BookAntiqua,serif;font-size:22.0pt;color:#414099">the oncolytic virus talimogene </span></b></p>
<p style="top:124.9pt;left:146.9pt;line-height:22.0pt"><b><span style="font-family:BookAntiqua,serif;font-size:22.0pt;color:#414099">laherparepvec (T- VEC): a </span></b></p>
<p style="top:150.9pt;left:146.9pt;line-height:22.0pt"><b><span style="font-family:BookAntiqua,serif;font-size:22.0pt;color:#414099">systematic review</span></b></p>
<p style="top:198.9pt;left:146.9pt;line-height:11.0pt"><span style="font-family:Arial,serif;font-size:11.0pt">Manoj Lalu   ,</span><sup><span style="font-family:Arial,serif;font-size:7.3pt">1,2,3,4</span></sup><span style="font-family:Arial,serif;font-size:11.0pt"> Garvin J Leung,</span><sup><span style="font-family:Arial,serif;font-size:7.3pt">1,5</span></sup><span style="font-family:Arial,serif;font-size:11.0pt"> Yuan Yi Dong,</span><sup><span style="font-family:Arial,serif;font-size:7.3pt">1,5</span></sup><span style="font-family:Arial,serif;font-size:11.0pt"> Joshua Montroy,</span><sup><span style="font-family:Arial,serif;font-size:7.3pt">1</span></sup><span style="font-family:Arial,serif;font-size:11.0pt"> </span></p>
<p style="top:211.9pt;left:146.9pt;line-height:11.0pt"><span style="font-family:Arial,serif;font-size:11.0pt">Claire Butler,</span><sup><span style="font-family:Arial,serif;font-size:7.3pt">1</span></sup><span style="font-family:Arial,serif;font-size:11.0pt"> Rebecca C Auer,</span><sup><span style="font-family:Arial,serif;font-size:7.3pt">6,7</span></sup><span style="font-family:Arial,serif;font-size:11.0pt"> Dean A Fergusson</span><sup><span style="font-family:Arial,serif;font-size:7.3pt">1,5,8</span></sup></p>
<p style="top:258.9pt;left:40.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">To cite: </span></b><span style="font-family:Arial,serif;font-size:8.0pt">Lalu&#xa0;M, Leung&#xa0;GJ, </span></p>
<p style="top:268.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Dong&#xa0;YY, </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">.  Mapping the </span></p>
<p style="top:278.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">preclinical to clinical evidence </span></p>
<p style="top:288.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">and development trajectory of </span></p>
<p style="top:298.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">the oncolytic virus talimogene </span></p>
<p style="top:308.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">laherparepvec (T- VEC): a </span></p>
<p style="top:318.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">systematic review.</span><i><span style="font-family:Arial,serif;font-size:8.0pt"> BMJ Open</span></i><span style="font-family:Arial,serif;font-size:8.0pt"> </span></p>
<p style="top:328.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">2019;</span><b><span style="font-family:Arial,serif;font-size:8.0pt">9</span></b><span style="font-family:Arial,serif;font-size:8.0pt">:e029475. doi:10.1136/</span></p>
<p style="top:338.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">bmjopen-2019-029475</span></p>
<p style="top:356.1pt;left:46.9pt;line-height:6.5pt"><span style="font-family:Arial,serif;font-size:6.5pt;color:#414099"> </span></p>
<p style="top:356.1pt;left:40.5pt;line-height:6.5pt"><span style="font-family:Arial,sans-serif;font-size:6.5pt;color:#414099">&#x25ba;</span><span style="font-family:Arial,serif;font-size:8.0pt"> Prepublication history and </span></p>
<p style="top:364.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">additional material for this paper </span></p>
<p style="top:374.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">are available online. To view </span></p>
<p style="top:384.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">please visit the journal (http://  </span></p>
<p style="top:394.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">dx. doi. org/ 10. 1136/ bmjopen- </span></p>
<p style="top:404.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">2019- 029475).</span></p>
<p style="top:423.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">ML and GJL contributed equally.</span></p>
<p style="top:442.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Received 30 January 2019</span></p>
<p style="top:452.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Revised 01 November 2019</span></p>
<p style="top:462.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Accepted 04 November 2019</span></p>
<p style="top:683.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">For numbered affiliations see </span></p>
<p style="top:693.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">end of article.</span></p>
<p style="top:712.9pt;left:40.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099">Correspondence to</span></b></p>
<p style="top:722.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Dr Dean A Fergusson;  </span></p>
<p style="top:732.9pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt"> dafergusson@ ohri. ca</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,68.66667,800.3334)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAFwAAAASCAYAAADWvblEAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAdElEQVR4nO3QMQqFMACD4dz/Yh06KBSeoEOhQwcdFFFUFOIt4vDy
w7eHgE4avh7wb/lwcT5cHO7noengOC+aDtZtp+lgXhaaDsZpoumg1krTQSmFpoOc
M00Hw9DTdNB1P5oOUko0HbRNQ9NBjJGmgxACTecFLVUDFbVVuJEAAAAASUVORK5CYII=">
<p style="top:25.1pt;left:459.2pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#ffffff">Original research</span></b></p>
<p style="top:623.2pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#xa9; Author(s) (or their </span></p>
<p style="top:632.8pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">employer(s)) 2019. Re- use </span></p>
<p style="top:642.4pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">permitted under CC BY- NC. No </span></p>
<p style="top:652.0pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">commercial re- use. See rights </span></p>
<p style="top:661.6pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">and permissions. Published by </span></p>
<p style="top:671.2pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">BMJ.</span></p>
<p style="top:258.7pt;left:146.9pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">AbstrACt</span></b></p>
<p style="top:270.5pt;left:146.9pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt">Objective </span></b><span style="font-family:Arial,serif;font-size:9.0pt">This study aimed to conduct a systematic </span></p>
<p style="top:281.5pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">review of preclinical and clinical evidence to chart the </span></p>
<p style="top:292.5pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">successful trajectory of talimogene laherparepvec (T- VEC) </span></p>
<p style="top:303.5pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">from the bench to the clinic.</span></p>
<p style="top:314.5pt;left:146.9pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt">Design </span></b><span style="font-family:Arial,serif;font-size:9.0pt">This study was a systematic review. The primary </span></p>
<p style="top:325.5pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">outcome of interest was the efficacy of treatment, </span></p>
<p style="top:336.5pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">determined by complete response. Abstract and full- text </span></p>
<p style="top:347.5pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">selection as well as data extraction were done by two </span></p>
<p style="top:358.5pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">independent reviewers. The Cochrane risk of bias tool was </span></p>
<p style="top:369.5pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">used to assess the risk of bias in studies.</span></p>
<p style="top:380.5pt;left:146.9pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt">setting </span></b><span style="font-family:Arial,serif;font-size:9.0pt">Embase, Embase Classic and OvidMedline were </span></p>
<p style="top:391.5pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">searched from inception until May 2016 to assess its </span></p>
<p style="top:402.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">development trajectory to approval in 2015.</span></p>
<p style="top:413.4pt;left:146.9pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt">Participants </span></b><span style="font-family:Arial,serif;font-size:9.0pt">Preclinical and clinical controlled </span></p>
<p style="top:424.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">comparison studies, as well as observational studies.</span></p>
<p style="top:435.4pt;left:146.9pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt">Interventions </span></b><span style="font-family:Arial,serif;font-size:9.0pt">T- VEC for the treatment of any malignancy.</span></p>
<p style="top:446.4pt;left:146.9pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt">results </span></b><span style="font-family:Arial,serif;font-size:9.0pt">8852 records were screened and five preclinical </span></p>
<p style="top:457.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">(n=150 animals) and seven clinical studies (n=589 </span></p>
<p style="top:468.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">patients) were included. We saw large decreases in T- </span></p>
<p style="top:479.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">VEC&#x2019;s efficacy as studies moved from the laboratory to </span></p>
<p style="top:490.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">patients, and as studies became more methodologically </span></p>
<p style="top:501.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">rigorous. Preclinical studies reported complete regression </span></p>
<p style="top:512.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">rates up to 100% for injected tumours and 80% for </span></p>
<p style="top:523.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">contralateral tumours, while the highest degree of efficacy </span></p>
<p style="top:534.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">seen in the clinical setting was a 24% complete response </span></p>
<p style="top:545.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">rate, with one study experiencing a complete response </span></p>
<p style="top:556.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">rate of 0%. We were unable to reliably assess safety due to </span></p>
<p style="top:567.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">the lack of reporting, as well as the heterogeneity seen in </span></p>
<p style="top:578.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">adverse event definitions. All preclinical studies had high or </span></p>
<p style="top:589.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">unclear risk of bias, and all clinical studies were at a high </span></p>
<p style="top:600.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">risk of bias in at least one domain.</span></p>
<p style="top:611.4pt;left:146.9pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt">Conclusions </span></b><span style="font-family:Arial,serif;font-size:9.0pt">Our findings illustrate that even successful </span></p>
<p style="top:622.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">biotherapeutics may not demonstrate a clear translational </span></p>
<p style="top:633.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">road map. This emphasises the need to consider </span></p>
<p style="top:644.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">increasing rigour and transparency along the translational </span></p>
<p style="top:655.4pt;left:146.9pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">pathway.</span></p>
<p style="top:666.4pt;left:146.9pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt">PrOsPErO registration number </span></b><span style="font-family:Arial,serif;font-size:9.0pt">CRD42016043541.</span></p>
<p style="top:695.3pt;left:146.9pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">bACkgrOunD</span></b></p>
<p style="top:707.3pt;left:146.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Preclinical research receives approximately </span></p>
<p style="top:719.3pt;left:146.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">half of the world&#x2019;s biomedical research </span></p>
<p style="top:731.3pt;left:146.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">funding, yet very few of its findings translate </span></p>
<p style="top:383.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">clinically. This represents an enormous waste </span></p>
<p style="top:395.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">of resources with an estimated US$28 billion </span></p>
<p style="top:407.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">dollars per year in the USA alone being spent </span></p>
<p style="top:419.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">on biomedical research which is not repro-</span></p>
<p style="top:431.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ducible and therefore not translatable.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">1</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> One </span></p>
<p style="top:443.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">study found that only 5% of highly efficacious </span></p>
<p style="top:455.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">preclinical therapeutics were clinically trans-</span></p>
<p style="top:467.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">lated.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">2</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> These successes often take almost 20 </span></p>
<p style="top:479.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">years to become successfully translated across </span></p>
<p style="top:491.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">the research spectrum.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">2 3</span></sup></p>
<p style="top:503.3pt;left:367.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Although the process of clinical trans-</span></p>
<p style="top:515.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">lation is complicated, the transition from </span></p>
<p style="top:527.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">bench- to- bedside often starts with preclinical </span></p>
<p style="top:539.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">research. These investigations (usually on </span></p>
<p style="top:551.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">animals or cells) are aimed at studying effi-</span></p>
<p style="top:563.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">cacy, pharmacokinetics and dynamics, as well </span></p>
<p style="top:575.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">as detailing safety.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">4</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> Next, a drug is tested in a </span></p>
<p style="top:587.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">phase I clinical trial, which usually contains a </span></p>
<p style="top:599.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">small number of participants and is aimed at </span></p>
<p style="top:611.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">studying the safety of the drug. If a drug is safe, </span></p>
<p style="top:623.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">it may proceed to phase II studies which are </span></p>
<p style="top:635.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">larger than phase I studies and are designed </span></p>
<p style="top:647.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">to test safety, pharmacokinetics, pharmacody-</span></p>
<p style="top:659.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">namics and optimal dosing regimens. They </span></p>
<p style="top:671.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">may also offer preliminary evidence of drug </span></p>
<p style="top:683.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">efficacy. Finally, a methodologically rigorous </span></p>
<p style="top:695.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">phase III study is performed. These studies </span></p>
<p style="top:707.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">are designed and powered to test efficacy in </span></p>
<p style="top:719.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">the patient population of interest (usually </span></p>
<p style="top:731.3pt;left:358.3pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">against a comparator such as placebo), as </span></p>
<p style="top:264.7pt;left:364.3pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#ffffff">strengths and limitations of this study</span></b></p>
<p style="top:287.4pt;left:372.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099"> </span></p>
<p style="top:287.4pt;left:364.3pt;line-height:8.0pt"><span style="font-family:Arial,sans-serif;font-size:8.0pt;color:#414099">&#x25ba;</span><span style="font-family:Arial,serif;font-size:9.0pt"> Comprehensive analysis of the translational path-</span></p>
<p style="top:297.6pt;left:376.3pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">way of talimogene laherparepvec.</span></p>
<p style="top:309.4pt;left:372.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099"> </span></p>
<p style="top:309.4pt;left:364.3pt;line-height:8.0pt"><span style="font-family:Arial,sans-serif;font-size:8.0pt;color:#414099">&#x25ba;</span><span style="font-family:Arial,serif;font-size:9.0pt"> Threats to both internal validity and construct valid-</span></p>
<p style="top:319.6pt;left:376.3pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">ity were assessed.</span></p>
<p style="top:331.4pt;left:372.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099"> </span></p>
<p style="top:331.4pt;left:364.3pt;line-height:8.0pt"><span style="font-family:Arial,sans-serif;font-size:8.0pt;color:#414099">&#x25ba;</span><span style="font-family:Arial,serif;font-size:9.0pt"> Reporting of methods and findings was incomplete </span></p>
<p style="top:341.6pt;left:376.3pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">in most of the studies included, which limited our </span></p>
<p style="top:352.6pt;left:376.3pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">analysis</span></p>
<p style="top:35.1pt;left:575.3pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">BMJ Open: first published as 10.1136/bmjopen-2019-029475 on 2 December 2019. Downloaded from </span><span style="font-family:Arial,sans-serif;font-size:9.0pt;color:#0000ff">http://bmjopen.bmj.com/</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> on March 2, 2023 by guest. Protected by copyright.</span></p>


<p style="top:758.1pt;left:40.5pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">2</span></b></p>
<p style="top:759.7pt;left:321.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lalu&#xa0;M, </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. </span><i><span style="font-family:Arial,serif;font-size:8.0pt">BMJ Open</span></i><span style="font-family:Arial,serif;font-size:8.0pt"> 2019;</span><b><span style="font-family:Arial,serif;font-size:8.0pt">9</span></b><span style="font-family:Arial,serif;font-size:8.0pt">:e029475. doi:10.1136/bmjopen-2019-029475</span></p>
<p style="top:25.1pt;left:44.3pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#ffffff">Open access </span></b></p>
<img style="position:absolute;transform:matrix(.74417206,0,-0,.74417206,74.85068,414.9948)" src="data:image/png;base64,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">
<p style="top:732.1pt;left:40.5pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt;color:#414099">Figure 1 </span></b><span style="font-family:Arial,serif;font-size:9.0pt">Study selection flow diagram.</span></p>
<p style="top:47.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">well as identify rarer adverse events which may have gone </span></p>
<p style="top:59.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">unnoticed in a smaller phase I or II study.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">5</span></sup></p>
<p style="top:71.3pt;left:49.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Given the high failure rate in translating therapies </span></p>
<p style="top:83.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">across this spectrum, as well as significant time- lags associ-</span></p>
<p style="top:95.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ated with translation, it is important that we examine the </span></p>
<p style="top:107.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">few agents that have successfully crossed the preclinical to </span></p>
<p style="top:119.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">clinical bridge in order to learn from and replicate their </span></p>
<p style="top:131.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">success. Thus, we conducted a comprehensive evaluation </span></p>
<p style="top:143.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">of available evidence supporting the successful transla-</span></p>
<p style="top:155.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">tion of talimogene laherparepvec (T- VEC). T- VEC is a </span></p>
<p style="top:167.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">modified Herpes Simplex Virus (HSV)-1 virus produced </span></p>
<p style="top:179.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">by Amgen and it is the first, and only, Food and Drug </span></p>
<p style="top:191.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Adminstration (FDA) approved oncolytic virus therapy; </span></p>
<p style="top:203.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">it is currently approved to treat advanced melanoma.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">6</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> </span></p>
<p style="top:215.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Oncolytic viruses are an emerging cancer therapy that </span></p>
<p style="top:227.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">work by preferentially targeting and infecting cancer </span></p>
<p style="top:239.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">cells.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">6</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> On infection, oncolytic viruses can induce an anti-</span></p>
<p style="top:251.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">tumour immune response that reduces tumour burden. </span></p>
<p style="top:263.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">T- VEC was chosen as a model due to the fact that it is the </span></p>
<p style="top:275.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">only approved oncolytic virus therapy to date, despite the </span></p>
<p style="top:287.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">multitude of agents under investigation.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">7</span></sup></p>
<p style="top:299.3pt;left:49.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Through a careful evaluation of T- VEC development, </span></p>
<p style="top:311.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">we hoped to identify factors that may contribute to bench- </span></p>
<p style="top:323.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">to- bedside success. This may serve an exemplar for other </span></p>
<p style="top:335.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">therapies as they move along the translational continuum. </span></p>
<p style="top:47.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Thus, the purpose of this systematic review was to map </span></p>
<p style="top:59.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">the successful preclinical to clinical trajectory of T- VEC to </span></p>
<p style="top:71.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">inform the development paths of future biotherapeutics.</span></p>
<p style="top:108.8pt;left:306.9pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">MEthODs</span></b></p>
<p style="top:120.8pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Our review was registered in full on PROSPERO,the inter-</span></p>
<p style="top:132.8pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">national prospective register of systematic reviews (no.</span></p>
<p style="top:144.8pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">CRD42016043541). The review is reported in accordance </span></p>
<p style="top:156.8pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">to the Preferred Reporting Items for Systematic Review </span></p>
<p style="top:168.8pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">and Meta- Analysis (PRISMA) guidelines.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">8</span></sup></p>
<p style="top:191.3pt;left:306.9pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">Eligibility criteria</span></b></p>
<p style="top:203.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">We included all clinical and preclinical in vivo controlled </span></p>
<p style="top:215.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">comparison studies of T- VEC for treatment of any </span></p>
<p style="top:227.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">malignancy (randomised, pseudo- randomised and non- </span></p>
<p style="top:239.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">randomised studies), as well as observational studies </span></p>
<p style="top:251.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">such as case- control, case- series and case reports. Studies </span></p>
<p style="top:263.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">reporting only ex vivo or in vitro experiments were </span></p>
<p style="top:275.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">excluded. For both preclinical and clinical studies, we </span></p>
<p style="top:287.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">included studies that administered T- VEC as a mono-</span></p>
<p style="top:299.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">therapy or in combination with other therapies for treat-</span></p>
<p style="top:311.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ment of malignancy. We had no exclusions on comparison </span></p>
<p style="top:323.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">treatments, which include standard line therapy or no </span></p>
<p style="top:335.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">treatment.</span></p>
<p style="top:35.1pt;left:575.3pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">BMJ Open: first published as 10.1136/bmjopen-2019-029475 on 2 December 2019. Downloaded from </span><span style="font-family:Arial,sans-serif;font-size:9.0pt;color:#0000ff">http://bmjopen.bmj.com/</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> on March 2, 2023 by guest. Protected by copyright.</span></p>


<p style="top:758.1pt;left:549.9pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">3</span></b></p>
<p style="top:759.7pt;left:40.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lalu&#xa0;M, </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. </span><i><span style="font-family:Arial,serif;font-size:8.0pt">BMJ Open</span></i><span style="font-family:Arial,serif;font-size:8.0pt"> 2019;</span><b><span style="font-family:Arial,serif;font-size:8.0pt">9</span></b><span style="font-family:Arial,serif;font-size:8.0pt">:e029475. doi:10.1136/bmjopen-2019-029475</span></p>
<p style="top:25.1pt;left:482.5pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#ffffff">Open access</span></b></p>
<p style="top:481.4pt;left:44.5pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt;color:#414099">Table 1 </span></b><span style="font-family:Arial,serif;font-size:9.0pt">Study characteristics of included preclinical studies of T- VEC</span></p>
<p style="top:506.4pt;left:44.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Preclinical study</span></b></p>
<p style="top:506.4pt;left:130.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Treatment</span></b></p>
<p style="top:496.2pt;left:211.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Total number of </span></b></p>
<p style="top:506.4pt;left:211.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">animals used</span></b></p>
<p style="top:506.4pt;left:281.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Type of cancer/model</span></b></p>
<p style="top:506.4pt;left:399.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Efficacy measures*</span></b></p>
<p style="top:496.2pt;left:512.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Risk of </span></b></p>
<p style="top:506.4pt;left:512.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">bias (/9</span></b><sup><b><span style="font-family:Arial,serif;font-size:5.6pt">&#x2020;</span></b></sup><b><span style="font-family:Arial,serif;font-size:8.5pt">)</span></b></p>
<p style="top:522.4pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Liu </span><i><span style="font-family:Arial,serif;font-size:8.5pt">et al</span></i><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">20</span></sup></p>
<p style="top:522.4pt;left:130.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">T- VEC; HSV1 wild </span></p>
<p style="top:532.6pt;left:130.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">type immunisation</span></p>
<p style="top:522.4pt;left:211.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">90</span></p>
<p style="top:522.4pt;left:281.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Lymphoma (A20 murine </span></p>
<p style="top:532.6pt;left:281.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">lymphoma mouse model)</span></p>
<p style="top:522.4pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">CR: 100% (n=10) (injected)</span></p>
<p style="top:522.4pt;left:512.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">9</span></p>
<p style="top:545.7pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Piasecki </span><i><span style="font-family:Arial,serif;font-size:8.5pt">et al</span></i><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">21</span></sup></p>
<p style="top:545.7pt;left:130.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">T- VEC</span></p>
<p style="top:545.7pt;left:211.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">NR</span></p>
<p style="top:545.7pt;left:281.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Lymphoma (A20 murine </span></p>
<p style="top:555.9pt;left:281.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">lymphoma mouse model)</span></p>
<p style="top:545.7pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">CR: 70%&#x2013;100% of injected, </span></p>
<p style="top:555.9pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">50%&#x2013;60% of contralateral</span></p>
<p style="top:545.7pt;left:512.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">9</span></p>
<p style="top:570.0pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Piasecki </span><i><span style="font-family:Arial,serif;font-size:8.5pt">et al</span></i><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">23</span></sup></p>
<p style="top:570.0pt;left:130.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">T- VEC +Anti- PD-1</span></p>
<p style="top:570.0pt;left:211.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">NR</span></p>
<p style="top:570.0pt;left:281.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Colorectal (MC-38 colon </span></p>
<p style="top:580.2pt;left:281.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">carcinoma mouse model)</span></p>
<p style="top:570.0pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">CR: 80.0% (44.2%&#x2013;96.5%) </span></p>
<p style="top:580.2pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">(injected) n=10</span></p>
<p style="top:590.4pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">CR: 20.0% (3.5%&#x2013;55.8%) </span></p>
<p style="top:600.6pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">(contralateral) n=10</span></p>
<p style="top:570.0pt;left:512.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">9</span></p>
<p style="top:614.6pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Cooke </span><i><span style="font-family:Arial,serif;font-size:8.5pt">et al</span></i><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">22</span></sup></p>
<p style="top:614.6pt;left:130.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">T- VEC</span></p>
<p style="top:614.6pt;left:211.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">40</span></p>
<p style="top:614.6pt;left:281.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Lymphoma (A20 murine </span></p>
<p style="top:624.8pt;left:281.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">lymphoma mouse model)</span></p>
<p style="top:614.6pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">CR: 100% (65.5%&#x2013;100%) </span></p>
<p style="top:624.8pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">(injected) n=10</span></p>
<p style="top:635.0pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">CR: 50% (23.7%&#x2013;76.3%) </span></p>
<p style="top:645.2pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">(contralateral)</span></p>
<p style="top:614.6pt;left:512.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">9</span></p>
<p style="top:658.3pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Cooke </span><i><span style="font-family:Arial,serif;font-size:8.5pt">et al</span></i><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">24</span></sup></p>
<p style="top:658.3pt;left:130.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">T- VEC</span></p>
<p style="top:658.3pt;left:211.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">20</span></p>
<p style="top:658.3pt;left:281.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Melanoma (B16F10 </span></p>
<p style="top:668.5pt;left:281.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">melanoma model)</span></p>
<p style="top:658.3pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">NR: statistically significant </span></p>
<p style="top:668.5pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">tumour reduction and </span></p>
<p style="top:678.7pt;left:399.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">survival noted</span></p>
<p style="top:658.3pt;left:512.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">9</span></p>
<p style="top:696.8pt;left:44.5pt;line-height:8.3pt"><span style="font-family:Arial,serif;font-size:8.3pt">* DR &#x2013; durable response; OR &#x2013; objective response; CR &#x2013; complete response/complete regression; PR &#x2013; partial response;DR/OR/CR/PR </span></p>
<p style="top:706.8pt;left:44.5pt;line-height:8.3pt"><span style="font-family:Arial,serif;font-size:8.3pt">definitions were based on RECIST guidelines for clinical studies. &#x2020; Total number of domains that were assessed a score of high risk or </span></p>
<p style="top:716.7pt;left:44.5pt;line-height:8.3pt"><span style="font-family:Arial,serif;font-size:8.3pt">unclear (maximum = 9).</span></p>
<p style="top:726.7pt;left:44.5pt;line-height:8.3pt"><span style="font-family:Arial,serif;font-size:8.3pt">CR, complete response; HSV, Herpes Simplex Virus; NR, Not reported; PR, partial response; T- VEC, talimogene laherparepvec.</span></p>
<p style="top:47.6pt;left:40.5pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">Outcomes</span></b></p>
<p style="top:59.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">The primary outcome of interest was the efficacy of treat-</span></p>
<p style="top:71.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ment. Our primary indicator of efficacy was complete </span></p>
<p style="top:83.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">response. Other measures of efficacy such as survival, </span></p>
<p style="top:95.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">response rates (durable, partial, objective), time to treat-</span></p>
<p style="top:107.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ment failure and disease stability were also collected. Such </span></p>
<p style="top:119.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">measures were based on the Response Evaluation Criteria </span></p>
<p style="top:131.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">in Solid Tumours Guidelines.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">9</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> In preclinical studies, addi-</span></p>
<p style="top:143.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">tional measures of efficacy such as changes in mean tumour </span></p>
<p style="top:155.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">volume and number of lesions were collected. The primary </span></p>
<p style="top:167.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">indicator of efficacy, complete response, was used as the </span></p>
<p style="top:179.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">primary outcome regardless of reporting within the indi-</span></p>
<p style="top:191.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">vidual study, in order to assess the continuity of evidence </span></p>
<p style="top:203.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">along the research spectrum. The secondary outcome of </span></p>
<p style="top:215.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">interest was safety, for which we collected data on all adverse </span></p>
<p style="top:227.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">events in preclinical and clinical studies.</span></p>
<p style="top:248.6pt;left:40.5pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">Literature search</span></b></p>
<p style="top:260.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">In collaboration with a medical information specialist </span></p>
<p style="top:272.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">(Risa Shorr, Learning Services, The Ottawa Hospital) </span></p>
<p style="top:284.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">a search strategy was designed to identify all relevant </span></p>
<p style="top:296.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">preclinical and clinical studies. Searches were conducted </span></p>
<p style="top:308.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">in the following databases: Embase, Embase Classic and </span></p>
<p style="top:320.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">OvidMedline from inception until May 2016. This time </span></p>
<p style="top:332.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">frame was chosen to ensure that all published studies </span></p>
<p style="top:344.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">which contributed T- VECs FDA approval in 2015 were </span></p>
<p style="top:356.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">included. Search terms included Talimogen laher-</span></p>
<p style="top:368.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">parepvec, Tvec, OncoVEX and Imlygic. Additional terms </span></p>
<p style="top:380.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">pertaining to preclinical studies (eg, animal experiment/</span></p>
<p style="top:392.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">model) and oncology (eg, cancer, neoplasm, oncolytic </span></p>
<p style="top:404.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">virus) were also included. Studies were also screened </span></p>
<p style="top:416.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">for inclusion based on reference tracking, by scanning </span></p>
<p style="top:428.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">the bibliography of included primary studies and rele-</span></p>
<p style="top:440.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">vant review articles. We did not impose any restrictions </span></p>
<p style="top:47.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">on language or publication type. A grey literature search </span></p>
<p style="top:59.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">was not performed. The finalised search strategy can be </span></p>
<p style="top:71.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">found in online supplementary file 1.</span></p>
<p style="top:92.4pt;left:306.9pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">study selection process</span></b></p>
<p style="top:104.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Studies identified by our literature search were collated and </span></p>
<p style="top:116.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">duplicates were removed. Titles and abstracts were inde-</span></p>
<p style="top:128.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">pendently screened for inclusion by two reviewers using </span></p>
<p style="top:140.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">DistillerSR (Evidence Partners, Ottawa, Ontario, Canada). </span></p>
<p style="top:152.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Those deemed potentially relevant were recorded, and full- </span></p>
<p style="top:164.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">text articles were obtained. The same reviewers screened </span></p>
<p style="top:176.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">full articles for final eligibility. Disagreements at any stage </span></p>
<p style="top:188.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">were resolved by discussion or consultation with a senior </span></p>
<p style="top:200.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">team member when necessary. The study selection process </span></p>
<p style="top:212.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">was documented using a PRISMA flow diagram.</span></p>
<p style="top:233.5pt;left:306.9pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">Data extraction</span></b></p>
<p style="top:245.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">All data extraction was completed independently and in </span></p>
<p style="top:257.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">duplicate, using a standardised and piloted data extraction </span></p>
<p style="top:269.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">form, with disagreements resolved as mentioned above. </span></p>
<p style="top:281.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Data pertaining to general and intervention characteristics </span></p>
<p style="top:293.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">of the included studies were extracted (eg, study design, </span></p>
<p style="top:305.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">country, type of malignancy, dosing of intervention and </span></p>
<p style="top:317.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">comparator treatments). For clinical studies, data was </span></p>
<p style="top:329.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">collected on patient characteristics (eg, age, sex, cancer </span></p>
<p style="top:341.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">staging, HSV status). For preclinical studies, characteristics </span></p>
<p style="top:353.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">on the animal model were extracted (eg, type of species, </span></p>
<p style="top:365.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">cell line used, disease induction method, age, sex, weight).</span></p>
<p style="top:380.6pt;left:306.9pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">risk of bias: assessment to risk of internal validity</span></b></p>
<p style="top:392.6pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Clinical studies that met inclusion criteria were assessed for </span></p>
<p style="top:404.6pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">risk of bias in duplicate, according to the recommended </span></p>
<p style="top:416.6pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">methodology of the Cochrane Collaboration.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">10</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> Five </span></p>
<p style="top:428.6pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">types of biases (selection, performance, detection, attri-</span></p>
<p style="top:440.6pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">tion, reporting biases) were assessed using six domains: </span></p>
<p style="top:35.1pt;left:575.3pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">BMJ Open: first published as 10.1136/bmjopen-2019-029475 on 2 December 2019. Downloaded from </span><span style="font-family:Arial,sans-serif;font-size:9.0pt;color:#0000ff">http://bmjopen.bmj.com/</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> on March 2, 2023 by guest. Protected by copyright.</span></p>


<p style="top:758.1pt;left:40.5pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">4</span></b></p>
<p style="top:759.7pt;left:321.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lalu&#xa0;M, </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. </span><i><span style="font-family:Arial,serif;font-size:8.0pt">BMJ Open</span></i><span style="font-family:Arial,serif;font-size:8.0pt"> 2019;</span><b><span style="font-family:Arial,serif;font-size:8.0pt">9</span></b><span style="font-family:Arial,serif;font-size:8.0pt">:e029475. doi:10.1136/bmjopen-2019-029475</span></p>
<p style="top:25.1pt;left:44.3pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#ffffff">Open access </span></b></p>
<p style="top:47.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">randomisation, allocation concealment, blinding of partic-</span></p>
<p style="top:59.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ipants/personnel, outcome assessment blinding, incom-</span></p>
<p style="top:71.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">plete outcome reporting and selective outcome reporting. </span></p>
<p style="top:83.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Additional domains assessed for risk of bias were (1) </span></p>
<p style="top:95.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">reported conflicts of interest, (2) sample size calculation </span></p>
<p style="top:107.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">and (3) funding. Each domain was given a score of &#x2018;high&#x2019;, </span></p>
<p style="top:119.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">&#x2018;unclear&#x2019; or &#x2018;low&#x2019; risk of bias for each study. Risk of bias </span></p>
<p style="top:131.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">assessment for preclinical studies were assessed using a </span></p>
<p style="top:143.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">modified Cochrane Risk of Bias tool and assessed the same </span></p>
<p style="top:155.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">domains as indicated for clinical studies.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">11</span></sup></p>
<p style="top:177.6pt;left:40.5pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">Assessment of threats to construct validity</span></b></p>
<p style="top:189.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Construct validity is the concept in how well a preclinical </span></p>
<p style="top:201.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">experiment (ie, animal studies) corresponds to the clinical </span></p>
<p style="top:213.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">entity it is intended to model. There are various threats to </span></p>
<p style="top:225.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">construct validity that can be introduced from the preclin-</span></p>
<p style="top:237.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ical study design. The items evaluated in duplicate for </span></p>
<p style="top:249.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">each preclinical study include (1) use of adult animals, </span></p>
<p style="top:261.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">(2) use of animals with advanced stage disease (defined as </span></p>
<p style="top:273.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">the presence of multiple visceral lesions and/or clinical/</span></p>
<p style="top:285.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">histological signs of malignant progression), (3) immune </span></p>
<p style="top:297.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">status of animals to HSV, (4) whether a xenograft model </span></p>
<p style="top:309.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">was used and (5) the use of a humanised immune system </span></p>
<p style="top:321.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">model. Each of these items was given a score of &#x2018;yes&#x2019;, &#x2018;no&#x2019; or </span></p>
<p style="top:333.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">&#x2018;unclear&#x2019; for every preclinical study.</span></p>
<p style="top:355.9pt;left:40.5pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">statistical analysis</span></b></p>
<p style="top:367.9pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Efficacy was expressed as proportions with accompanying </span></p>
<p style="top:379.9pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">95% CIs. If CIs were not present within the individual study, </span></p>
<p style="top:391.9pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">they were calculated via standard methods.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">12</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> To assess the </span></p>
<p style="top:403.9pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">continuity between preclinical and clinical studies, the effi-</span></p>
<p style="top:415.9pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">cacy of studies was plotted as percentage response.</span></p>
<p style="top:438.2pt;left:40.5pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">Deviations from protocol</span></b></p>
<p style="top:450.2pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">We were unable to assess safety as we could not acquire </span></p>
<p style="top:462.2pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">patient- level safety data. Furthermore, our primary efficacy </span></p>
<p style="top:474.2pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">outcome stated in the protocol was durable response rate. </span></p>
<p style="top:486.2pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">However, this was changed to complete response as most </span></p>
<p style="top:498.2pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">clinical studies did not report durable response, and we </span></p>
<p style="top:510.2pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">needed to track T- VEC&#x2019;s trajectory over several studies. We </span></p>
<p style="top:522.2pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">acknowledge the limitation of this approach, given the FDA </span></p>
<p style="top:534.2pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">approved T- VEC based on the OPTIM trial,</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">13</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> the primary </span></p>
<p style="top:546.1pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">endpoint of which was durable response rate. Subgroup </span></p>
<p style="top:558.1pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">analyses, meta- analyses, Egger&#x2019;s test and pooling of data </span></p>
<p style="top:570.1pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">could not be conducted due to the limited available data.</span></p>
<p style="top:592.4pt;left:40.5pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">Patient and public involvement</span></b></p>
<p style="top:604.4pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Patients and the public were not involved in this research.</span></p>
<p style="top:635.3pt;left:40.5pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">rEsuLts</span></b></p>
<p style="top:647.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">On removal of duplicates, a total of 8852 references were </span></p>
<p style="top:659.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">identified by the electronic search. During the review of titles </span></p>
<p style="top:671.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">and abstracts, 7890 references were excluded. Following </span></p>
<p style="top:683.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">full- text screening, another 938 articles were excluded </span></p>
<p style="top:695.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">for reasons such as wrong study design (ie, review article) </span></p>
<p style="top:707.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">or wrong study intervention (ie, a different cancer thera-</span></p>
<p style="top:719.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">peutic). A total of seven clinical studies</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">13&#x2013;19</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> and five preclin-</span></p>
<p style="top:731.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ical studies</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">20&#x2013;24</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> were included in our review (</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt;color:#0000ff">figure 1</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt">).</span></p>
<p style="top:47.6pt;left:306.9pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">Characteristics of included trials</span></b></p>
<p style="top:59.8pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Characteristics of included preclinical studies are shown </span></p>
<p style="top:72.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">in </span><span style="font-family:NewBaskerville,serif;font-size:10.0pt;color:#0000ff">table 1</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt">. Preclinical studies were published between </span></p>
<p style="top:84.2pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">2003 and 2016 and sample sizes ranged from 20 to 90. Of </span></p>
<p style="top:96.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">the five preclinical studies, three used a lymphoma model, </span></p>
<p style="top:108.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">one used a colorectal model and one used a melanoma </span></p>
<p style="top:120.7pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">model. All studies were performed in mice. The duration </span></p>
<p style="top:132.8pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">of follow- up was reported by two studies and ranged from </span></p>
<p style="top:145.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">10 to 35 days. The dose of T- VEC used ranged from 3&#xd7;10</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt">4</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> </span></p>
<p style="top:157.2pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">plaque forming units (PFU) to 5&#xd7;10</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt">6</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> PFU. Frequency </span></p>
<p style="top:169.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">of T- VEC administration varied: every 3 days for 1 week, </span></p>
<p style="top:181.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">every 3 days for 9 days, a single dose given only once and </span></p>
<p style="top:193.7pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">every other day for 5 days. Specific details of study and </span></p>
<p style="top:205.9pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">intervention characteristics for each preclinical study can </span></p>
<p style="top:218.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">be found in online supplementary files 2 and 3.</span></p>
<p style="top:230.2pt;left:315.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Characteristics of included clinical studies are shown in </span></p>
<p style="top:242.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt;color:#0000ff">table 2</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt">. Studies were published between 2006 and 2016 </span></p>
<p style="top:254.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">and took place in seven countries. Sample sizes ranged </span></p>
<p style="top:266.7pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">from 17 to 295. Of the seven clinical studies, four were in </span></p>
<p style="top:278.9pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">melanoma patients, one was in pancreatic cancer patients, </span></p>
<p style="top:291.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">one in head and neck cancer patients and one studied a </span></p>
<p style="top:303.2pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">mix of breast, colorectal, melanoma and head and neck </span></p>
<p style="top:315.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">cancer patients. Six were either phase I or II, and one </span></p>
<p style="top:327.6pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">trial was a phase III evaluation. The primary outcome was </span></p>
<p style="top:339.7pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">efficacy in two studies, safety in three studies and a combi-</span></p>
<p style="top:351.9pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">nation of efficacy and safety in the other two studies. The </span></p>
<p style="top:364.1pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">duration of follow- up ranged from 6 weeks to 44 months.</span></p>
<p style="top:376.2pt;left:315.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">T- VEC was administered alone in four studies, while it was </span></p>
<p style="top:388.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">administered immediately following to systemic therapy in </span></p>
<p style="top:400.6pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">three studies. The dose of T- VEC administered ranged from </span></p>
<p style="top:412.7pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">10</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt">4</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> to 10</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt">8</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> PFU/mL. In the large study, phase III, T- VEC </span></p>
<p style="top:424.9pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">was administered at </span><span style="font-family:Symbol,serif;font-size:10.0pt">&#x2264;</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt">4 mL &#xd7; 10</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt">6</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> PFU/mL once, and then </span></p>
<p style="top:437.1pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">3 weeks later, </span><span style="font-family:Symbol,serif;font-size:10.0pt">&#x2264;</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt">4 mL 10</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt">8</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> PFU/mL was administered every </span></p>
<p style="top:449.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">2 weeks for a median of 23 weeks. A similar dosing regimen </span></p>
<p style="top:461.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">was used in three other trials. The other three trials were </span></p>
<p style="top:473.6pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">dose- finding in nature and had multiple trial arms receiving </span></p>
<p style="top:485.8pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">increasing doses of T- VEC. In- depth study details, as well as </span></p>
<p style="top:497.9pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">participant and intervention details for each study, can be </span></p>
<p style="top:510.1pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">found in online supplementary files 4-6.</span></p>
<p style="top:536.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">Efficacy of treatment</span></p>
<p style="top:548.7pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Treatment efficacy for each study is summarised in </span></p>
<p style="top:560.8pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt;color:#0000ff">table 1</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt">, </span><span style="font-family:NewBaskerville,serif;font-size:10.0pt;color:#0000ff">table 2</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> and </span><span style="font-family:NewBaskerville,serif;font-size:10.0pt;color:#0000ff">figure 2</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt">. Preclinical studies reported </span></p>
<p style="top:573.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">complete regression rates up to 100% for injected </span></p>
<p style="top:585.2pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">tumours and 80% for contralateral tumours (see </span></p>
<p style="top:597.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">also online supplementary file 7). In comparison, the </span></p>
<p style="top:609.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">first published phase I T- VEC clinical trial reported a </span></p>
<p style="top:621.7pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">complete response of 0% for cutaneous lesions caused </span></p>
<p style="top:633.9pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">by malignancies of head and neck, breast, colorectal and </span></p>
<p style="top:646.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">melanoma. Of the multiple malignancies treated, mela-</span></p>
<p style="top:658.2pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">noma had the best response in this trial. Subsequent </span></p>
<p style="top:670.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">phase I/II melanoma trials were then conducted and </span></p>
<p style="top:682.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">demonstrated complete response rates of 20%&#x2013;22%. </span></p>
<p style="top:694.7pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">This was followed by the phase III OPTIM melanoma </span></p>
<p style="top:706.9pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">trial, which had a complete response rate of 10.8%. </span></p>
<p style="top:719.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Studies involving non- melanoma cancers varied with </span></p>
<p style="top:731.2pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">efficacies between 0% and 24%.</span></p>
<p style="top:35.1pt;left:575.3pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">BMJ Open: first published as 10.1136/bmjopen-2019-029475 on 2 December 2019. Downloaded from </span><span style="font-family:Arial,sans-serif;font-size:9.0pt;color:#0000ff">http://bmjopen.bmj.com/</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> on March 2, 2023 by guest. Protected by copyright.</span></p>


<p style="top:758.1pt;left:550.1pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">5</span></b></p>
<p style="top:759.7pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lalu&#xa0;M, </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. </span><i><span style="font-family:Arial,serif;font-size:8.0pt">BMJ Open</span></i><span style="font-family:Arial,serif;font-size:8.0pt"> 2019;</span><b><span style="font-family:Arial,serif;font-size:8.0pt">9</span></b><span style="font-family:Arial,serif;font-size:8.0pt">:e029475. doi:10.1136/bmjopen-2019-029475</span></p>
<p style="top:25.1pt;left:482.6pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#ffffff">Open access</span></b></p>
<p style="top:53.2pt;left:44.5pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt;color:#414099">Table 2 </span></b><span style="font-family:Arial,serif;font-size:9.0pt">Study characteristics of included clinical studies of T- VEC</span></p>
<p style="top:67.9pt;left:44.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Clinical study</span></b></p>
<p style="top:67.9pt;left:133.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Treatment</span></b></p>
<p style="top:67.9pt;left:214.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Total N</span></b></p>
<p style="top:67.9pt;left:276.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Type of cancer</span></b></p>
<p style="top:67.9pt;left:369.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Efficacy measures*</span></b></p>
<p style="top:67.9pt;left:482.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Risk of bias (/9</span></b><sup><b><span style="font-family:Arial,serif;font-size:5.6pt">&#x2020;</span></b></sup><b><span style="font-family:Arial,serif;font-size:8.5pt">)</span></b></p>
<p style="top:84.0pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Hu </span><i><span style="font-family:Arial,serif;font-size:8.5pt">et al</span></i><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">14</span></sup></p>
<p style="top:94.2pt;left:44.5pt;line-height:8.5pt"><i><span style="font-family:Arial,serif;font-size:8.5pt">Non- controlled</span></i></p>
<p style="top:104.4pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">phase I</span></p>
<p style="top:84.0pt;left:133.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">T- VEC</span></p>
<p style="top:84.0pt;left:214.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">30 (9 </span></p>
<p style="top:94.2pt;left:214.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">melanoma)</span></p>
<p style="top:84.0pt;left:276.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Breast, colorectal, </span></p>
<p style="top:94.2pt;left:276.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">melanoma, head and </span></p>
<p style="top:104.4pt;left:276.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">neck</span></p>
<p style="top:84.0pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">CR: 0% (0%&#x2013;14.1%)</span></p>
<p style="top:94.2pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">PR: 0% (0%&#x2013;14.1%)</span></p>
<p style="top:84.0pt;left:482.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">7</span></p>
<p style="top:117.5pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Senzer </span><i><span style="font-family:Arial,serif;font-size:8.5pt">et al</span></i><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">15</span></sup></p>
<p style="top:127.7pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Non- controlled</span></p>
<p style="top:137.9pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">phase II</span></p>
<p style="top:117.5pt;left:133.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">T- VEC</span></p>
<p style="top:117.5pt;left:214.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">50</span></p>
<p style="top:117.5pt;left:276.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Melanoma</span></p>
<p style="top:117.5pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">OR: 26.0% (15.1%&#x2013;40.6%)</span></p>
<p style="top:127.7pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">CR: 20.0% (10.5%&#x2013;34.1%)</span></p>
<p style="top:137.9pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">PR: 10.0% (3.7%&#x2013;22.6%)</span></p>
<p style="top:117.5pt;left:482.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">7</span></p>
<p style="top:152.0pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Harrington </span><i><span style="font-family:Arial,serif;font-size:8.5pt">et al</span></i><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">18</span></sup></p>
<p style="top:162.2pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">phase I/II</span></p>
<p style="top:152.0pt;left:133.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">T- VEC +cisplatin</span></p>
<p style="top:152.0pt;left:214.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">17</span></p>
<p style="top:152.0pt;left:276.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Head and neck</span></p>
<p style="top:152.0pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">CR: 23.5% (7.8%&#x2013;50.2%)</span></p>
<p style="top:162.2pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">PR: 58.8% (33.5%&#x2013;80.6%)</span></p>
<p style="top:172.4pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">OR: 82.4% (55.8%&#x2013;95.3%)</span></p>
<p style="top:152.0pt;left:482.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">6</span></p>
<p style="top:186.4pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Chang </span><i><span style="font-family:Arial,serif;font-size:8.5pt">et al</span></i><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">19</span></sup></p>
<p style="top:196.6pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">phase I</span></p>
<p style="top:186.4pt;left:133.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">T- VEC</span></p>
<p style="top:186.4pt;left:214.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">17</span></p>
<p style="top:186.4pt;left:276.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Pancreatic</span></p>
<p style="top:186.4pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">OR: 0% (0%&#x2013;22.9%)</span></p>
<p style="top:186.4pt;left:482.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">6</span></p>
<p style="top:210.7pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Andtbacka </span><i><span style="font-family:Arial,serif;font-size:8.5pt">et al</span></i><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">13</span></sup></p>
<p style="top:220.9pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">phase III</span></p>
<p style="top:210.7pt;left:133.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">T- VEC</span></p>
<p style="top:210.7pt;left:214.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">295</span></p>
<p style="top:210.7pt;left:276.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Melanoma</span></p>
<p style="top:210.7pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">DR: 16.3% (12.1%&#x2013;20.5%)</span></p>
<p style="top:220.9pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">OR: 26.4% (21.4%&#x2013;31.5%)</span></p>
<p style="top:231.1pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">PR: 15.6% (11.7%&#x2013;20.3%)</span></p>
<p style="top:241.3pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">CR: 10.8% (7.6%&#x2013;15.1%)</span></p>
<p style="top:210.7pt;left:482.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">3</span></p>
<p style="top:255.4pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">  </span></p>
<p style="top:255.4pt;left:133.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">GM- CSF (control)</span></p>
<p style="top:255.4pt;left:214.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">141</span></p>
<p style="top:255.4pt;left:276.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">  </span></p>
<p style="top:255.4pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">DR: 2.1% (0%&#x2013;4.5%)</span></p>
<p style="top:265.6pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">OR: 5.7% (1.9%&#x2013;9.5%)</span></p>
<p style="top:275.8pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">PR: 5.0% (1.3%&#x2013;8.5%)</span></p>
<p style="top:286.0pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">CR:&lt;1%</span></p>
<p style="top:300.0pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Long </span><i><span style="font-family:Arial,serif;font-size:8.5pt">et al</span></i><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">16</span></sup></p>
<p style="top:310.2pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">phase Ib</span></p>
<p style="top:300.0pt;left:133.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">T- VEC </span></p>
<p style="top:310.2pt;left:133.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">+pembrolizumab</span></p>
<p style="top:300.0pt;left:214.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">21</span></p>
<p style="top:300.0pt;left:276.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Melanoma</span></p>
<p style="top:300.0pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">&#x2013;</span></p>
<p style="top:300.0pt;left:482.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">6</span></p>
<p style="top:323.3pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Puzanov </span><i><span style="font-family:Arial,serif;font-size:8.5pt">et al</span></i><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">17</span></sup></p>
<p style="top:333.5pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">phase Ib</span></p>
<p style="top:323.3pt;left:133.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">T- VEC+IPI</span></p>
<p style="top:323.3pt;left:214.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">18</span></p>
<p style="top:323.3pt;left:276.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Melanoma</span></p>
<p style="top:323.3pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">DR: 44.4% (22.4%&#x2013;68.7%)</span></p>
<p style="top:333.5pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">OR: 50.0% (29.0%&#x2013;70.9%)</span></p>
<p style="top:343.7pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">CR: 22.2% (7.4%&#x2013;48.1%)</span></p>
<p style="top:353.9pt;left:369.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">PR: 27.8% (10.7%&#x2013;53.6%)</span></p>
<p style="top:323.3pt;left:482.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">6</span></p>
<p style="top:372.0pt;left:44.5pt;line-height:8.3pt"><span style="font-family:Arial,serif;font-size:8.3pt">*Definitions of DR/OR/CR/PR were based on RECIST guidelines for clinical studies.</span></p>
<p style="top:381.9pt;left:44.5pt;line-height:8.3pt"><span style="font-family:Arial,serif;font-size:8.3pt">&#x2020;Total number of domains that were assessed a score of high risk or unclear (maximum=9). The nine domains include randomisation, </span></p>
<p style="top:391.9pt;left:44.5pt;line-height:8.3pt"><span style="font-family:Arial,serif;font-size:8.3pt">allocation concealment, blinding of participants/personnel, outcome assessment blinding, incomplete outcome reporting, selective </span></p>
<p style="top:401.9pt;left:44.5pt;line-height:8.3pt"><span style="font-family:Arial,serif;font-size:8.3pt">outcome reporting, reported conflicts of interest, sample size calculation and funding.</span></p>
<p style="top:411.8pt;left:44.5pt;line-height:8.3pt"><span style="font-family:Arial,serif;font-size:8.3pt">CR, complete response/complete regression; DR, durable response; IPI, Ipilimumab; OR, objective response; PR, partial response; </span></p>
<p style="top:421.8pt;left:44.5pt;line-height:8.3pt"><span style="font-family:Arial,serif;font-size:8.3pt">RECIST, Response Evaluation Criteria in Solid Tumours; T- VEC, talimogene laherparepvec.</span></p>
<p style="top:462.4pt;left:40.5pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">Safety of treatment</span></p>
<p style="top:474.5pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">We attempted to assess safety across clinical studies; </span></p>
<p style="top:486.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">however, we were unable to obtain patient- level data from </span></p>
<p style="top:498.7pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">any of the studies. The definitions of adverse events, and </span></p>
<p style="top:510.8pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">the manner in which they were classified, were found to </span></p>
<p style="top:523.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">be highly heterogenous across studies. Studies did not </span></p>
<p style="top:535.1pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">specify what percent of adverse events were repeated </span></p>
<p style="top:547.2pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">adverse events from the same patient(s), used different </span></p>
<p style="top:559.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">criteria for recording and reporting adverse events, and </span></p>
<p style="top:571.4pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">categorised them differently. Therefore, we were unable </span></p>
<p style="top:583.6pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">to pool adverse events or interpret findings reliably.</span></p>
<p style="top:609.9pt;left:40.5pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">Validity assessments</span></p>
<p style="top:622.1pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Construct validity, the concept of how well an animal </span></p>
<p style="top:634.2pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">model represents the clinical entity it is intended to </span></p>
<p style="top:646.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">mimic, was first assessed through the following domains: </span></p>
<p style="top:658.4pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">the use of appropriately aged mice, advanced stage of </span></p>
<p style="top:670.5pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">disease, HSV- immunity and types of mouse models. None </span></p>
<p style="top:682.7pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">of the preclinical studies fully reported or used method-</span></p>
<p style="top:694.8pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ologies to reduce threats to construct validity domains </span></p>
<p style="top:706.9pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">(</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt;color:#0000ff">table 3</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt">). No studies declared using adult animal models, </span></p>
<p style="top:719.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">no studies used animals with late stage disease, only one </span></p>
<p style="top:731.1pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">study used animals immune to HSV, no studies used a </span></p>
<p style="top:462.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">xenograft model and no studies reported using an animal </span></p>
<p style="top:474.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">model with a humanised immune system.</span></p>
<p style="top:486.0pt;left:315.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">We also assessed internal validity (ie, risk of bias) and </span></p>
<p style="top:498.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">found that all preclinical studies had high or unclear </span></p>
<p style="top:510.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">risk of bias across the assessed domains: randomisation </span></p>
<p style="top:522.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">sequence, allocation concealment, blinding, incomplete </span></p>
<p style="top:534.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">reporting, sample size calculation and funding source </span></p>
<p style="top:546.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">(</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt;color:#0000ff">table 4</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt">). For clinical studies, early phase trials had high </span></p>
<p style="top:558.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">or unclear risk of bias across at least six of nine domains, </span></p>
<p style="top:570.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">whereas the more robust phase III OPTIM trial had the </span></p>
<p style="top:582.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">lowest risk of bias and also the lowest efficacy of any of the </span></p>
<p style="top:594.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">published melanoma clinical trials (</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt;color:#0000ff">table 5</span><span style="font-family:NewBaskerville,serif;font-size:10.0pt">). Reporting of </span></p>
<p style="top:606.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">key methodological elements was lacking.</span></p>
<p style="top:647.3pt;left:306.9pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">DIsCussIOn</span></b></p>
<p style="top:659.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">We hoped to synthesise the evidence to produce a clear </span></p>
<p style="top:671.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">road map of T- VEC&#x2019;s translation in the published liter-</span></p>
<p style="top:683.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ature. This would allow us to follow the journey of a </span></p>
<p style="top:695.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">successful biotherapeutic, and potentially use this as a </span></p>
<p style="top:707.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">blueprint for similar efforts in the future. Yet, we were </span></p>
<p style="top:719.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">unable to paint a clear picture of how the evidence was </span></p>
<p style="top:731.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">used in proceeding to melanoma clinical trials. Rather, </span></p>
<p style="top:35.1pt;left:575.3pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">BMJ Open: first published as 10.1136/bmjopen-2019-029475 on 2 December 2019. Downloaded from </span><span style="font-family:Arial,sans-serif;font-size:9.0pt;color:#0000ff">http://bmjopen.bmj.com/</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> on March 2, 2023 by guest. Protected by copyright.</span></p>


<p style="top:758.1pt;left:40.5pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">6</span></b></p>
<p style="top:759.7pt;left:321.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lalu&#xa0;M, </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. </span><i><span style="font-family:Arial,serif;font-size:8.0pt">BMJ Open</span></i><span style="font-family:Arial,serif;font-size:8.0pt"> 2019;</span><b><span style="font-family:Arial,serif;font-size:8.0pt">9</span></b><span style="font-family:Arial,serif;font-size:8.0pt">:e029475. doi:10.1136/bmjopen-2019-029475</span></p>
<p style="top:25.1pt;left:44.3pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#ffffff">Open access </span></b></p>
<img style="position:absolute;transform:matrix(.7412988,0,-0,.7412988,26.850678,5.1656496)" src="data:image/png;base64,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">
<p style="top:308.8pt;left:40.5pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt;color:#414099">Figure 2 </span></b><span style="font-family:Arial,serif;font-size:9.0pt">Preclinical and clinical efficacy of T- VEC. Four preclinical studies using mice demonstrated efficacy rates of 20%&#x2013;</span></p>
<p style="top:319.6pt;left:40.5pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">100% and clinical studies (three melanoma and two mixed malignancy studies) demonstrated efficacy rates from 0% to 23.5%. </span></p>
<p style="top:330.4pt;left:40.5pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">Non- melanoma/mixed studies are represented by blue bars, whereas melanoma studies are represented by orange bars. Where </span></p>
<p style="top:341.2pt;left:40.5pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">possible, complete regression rates of contralateral tumours for mice were used in preclinical studies and complete response </span></p>
<p style="top:352.0pt;left:40.5pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">was used for clinical studies. Efficacy rates decrease in the preclinical to clinical translation and on more rigorous study design </span></p>
<p style="top:362.8pt;left:40.5pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">in later phase clinical trials. Error bars are plotted and represent 95% CIs. Some studies were not included in this analysis as </span></p>
<p style="top:373.6pt;left:40.5pt;line-height:9.0pt"><span style="font-family:Arial,serif;font-size:9.0pt">they did not report the outcome of CR. CR, complete response; T- VEC, talimogene laherparepvec.</span></p>
<p style="top:603.1pt;left:44.5pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt;color:#414099">Table 3 </span></b><span style="font-family:Arial,serif;font-size:9.0pt">Construct validity assessment for preclinical studies</span></p>
<p style="top:638.2pt;left:44.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">First author, year</span></b></p>
<p style="top:638.2pt;left:143.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Adult used</span></b></p>
<p style="top:628.0pt;left:216.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Animals with advanced </span></b></p>
<p style="top:638.2pt;left:216.5pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">stage disease</span></b></p>
<p style="top:628.0pt;left:321.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Animals immune </span></b></p>
<p style="top:638.2pt;left:321.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">to HSV</span></b></p>
<p style="top:628.0pt;left:398.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Xenograft model </span></b></p>
<p style="top:638.2pt;left:398.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">used</span></b></p>
<p style="top:617.8pt;left:481.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Used model with </span></b></p>
<p style="top:628.0pt;left:481.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">a Humanised </span></b></p>
<p style="top:638.2pt;left:481.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">immune system</span></b></p>
<p style="top:654.3pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Cooke, 2016</span><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">24</span></sup></p>
<p style="top:654.3pt;left:143.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:654.3pt;left:216.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">No</span></p>
<p style="top:654.3pt;left:321.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:654.3pt;left:398.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">No</span></p>
<p style="top:654.3pt;left:481.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:667.4pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Cooke, 2015</span><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">22</span></sup></p>
<p style="top:667.4pt;left:143.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:667.4pt;left:216.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">No</span></p>
<p style="top:667.4pt;left:321.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:667.4pt;left:398.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">No</span></p>
<p style="top:667.4pt;left:481.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:681.4pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Piasecki, 2015</span><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">23</span></sup></p>
<p style="top:681.4pt;left:143.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:681.4pt;left:216.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:681.4pt;left:321.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:681.4pt;left:398.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">No</span></p>
<p style="top:681.4pt;left:481.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:695.5pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Piasecki, 2013</span><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">21</span></sup></p>
<p style="top:695.5pt;left:143.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:695.5pt;left:216.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:695.5pt;left:321.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:695.5pt;left:398.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">No</span></p>
<p style="top:695.5pt;left:481.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:708.6pt;left:44.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Liu, 2003</span><sup><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">20</span></sup></p>
<p style="top:708.6pt;left:143.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:708.6pt;left:216.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">No</span></p>
<p style="top:708.6pt;left:321.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Yes</span></p>
<p style="top:708.6pt;left:398.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">No</span></p>
<p style="top:708.6pt;left:481.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:726.7pt;left:44.5pt;line-height:8.3pt"><span style="font-family:Arial,serif;font-size:8.3pt">HSV, Herpes Simplex Virus.</span></p>
<p style="top:407.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">our assessment uncovered a disconnect between in vivo </span></p>
<p style="top:419.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">preclinical and clinical findings. Furthermore, the road </span></p>
<p style="top:431.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">map was plagued with poor reporting, high risk of bias </span></p>
<p style="top:443.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">and insufficient data along the translational path. Overall, </span></p>
<p style="top:455.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">we were surprised by the pace and magnitude of dimin-</span></p>
<p style="top:467.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ishing efficacy as T- VEC moved from bench- to- bedside </span></p>
<p style="top:479.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">and then towards later phase clinical trials (ie, phase I to </span></p>
<p style="top:491.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">III). Although T- VEC was successful in terms of gaining </span></p>
<p style="top:503.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">regulatory approval, its translational path is compli-</span></p>
<p style="top:515.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">cated and the pieces of the evidence puzzle do not easily </span></p>
<p style="top:527.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">fit together. While we appreciate that translation is not </span></p>
<p style="top:539.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">a predictable linear process, it is difficult to learn from </span></p>
<p style="top:551.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">the example of T- VEC given the available and reported </span></p>
<p style="top:563.0pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">preclinical and clinical evidence.</span></p>
<p style="top:407.0pt;left:315.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">While many novel therapeutics are under intellectual </span></p>
<p style="top:419.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">property rights, details of study design and results should be </span></p>
<p style="top:431.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">transparently reported for scientists, clinicians and patients </span></p>
<p style="top:443.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">to evaluate findings. The fact that the only FDA approved </span></p>
<p style="top:455.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">oncolytic virus therapy is not clearly reported illustrates the </span></p>
<p style="top:467.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">issues plaguing the success of cancer therapeutics. None-</span></p>
<p style="top:479.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">theless, T- VEC has shown some efficacy in treating refrac-</span></p>
<p style="top:491.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">tory melanoma</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">25</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> and numerous clinical trials are underway </span></p>
<p style="top:503.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">to assess its use in combination with other cancer regimens </span></p>
<p style="top:515.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">and in treating other malignancies. It is also the recom-</span></p>
<p style="top:527.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">mended treatment by the National Comprehensive Cancer </span></p>
<p style="top:539.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Centre for patients with in- transit melanoma.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">26</span></sup></p>
<p style="top:551.0pt;left:315.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Perhaps the largest discrepancy noted was that only a </span></p>
<p style="top:563.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">single preclinical study used a melanoma model, whereas </span></p>
<p style="top:35.1pt;left:575.3pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">BMJ Open: first published as 10.1136/bmjopen-2019-029475 on 2 December 2019. Downloaded from </span><span style="font-family:Arial,sans-serif;font-size:9.0pt;color:#0000ff">http://bmjopen.bmj.com/</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> on March 2, 2023 by guest. Protected by copyright.</span></p>


<p style="top:758.1pt;left:550.1pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">7</span></b></p>
<p style="top:759.7pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lalu&#xa0;M, </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. </span><i><span style="font-family:Arial,serif;font-size:8.0pt">BMJ Open</span></i><span style="font-family:Arial,serif;font-size:8.0pt"> 2019;</span><b><span style="font-family:Arial,serif;font-size:8.0pt">9</span></b><span style="font-family:Arial,serif;font-size:8.0pt">:e029475. doi:10.1136/bmjopen-2019-029475</span></p>
<p style="top:25.1pt;left:482.6pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#ffffff">Open access</span></b></p>
<p style="top:728.1pt;left:106.1pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt;color:#414099">Table 4 </span></b><span style="font-family:Arial,serif;font-size:9.0pt">Risk of bias assessment for preclinical studies</span></p>
<p style="top:728.5pt;left:122.9pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Author, Year</span></b></p>
<p style="top:658.5pt;left:122.9pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Random </span></b></p>
<p style="top:658.5pt;left:133.1pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Sequence </span></b></p>
<p style="top:658.5pt;left:143.3pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Generation</span></b></p>
<p style="top:586.5pt;left:122.9pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Allocation </span></b></p>
<p style="top:586.5pt;left:133.1pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Concealment</span></b></p>
<p style="top:522.5pt;left:122.9pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Blinding of </span></b></p>
<p style="top:522.5pt;left:133.1pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Personnel</span></b></p>
<p style="top:454.5pt;left:122.9pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Blinded Outcome </span></b></p>
<p style="top:454.5pt;left:133.1pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Assessment</span></b></p>
<p style="top:377.9pt;left:122.9pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Incomplete </span></b></p>
<p style="top:377.9pt;left:133.1pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Outcomes </span></b></p>
<p style="top:377.9pt;left:143.3pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Addressed</span></b></p>
<p style="top:298.9pt;left:122.9pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Selective </span></b></p>
<p style="top:298.9pt;left:133.1pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Outcome </span></b></p>
<p style="top:298.9pt;left:143.3pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Reporting</span></b></p>
<p style="top:230.9pt;left:122.9pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Conflicts of </span></b></p>
<p style="top:230.9pt;left:133.1pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Interest</span></b></p>
<p style="top:170.9pt;left:122.9pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">A Priori Sample </span></b></p>
<p style="top:170.9pt;left:133.1pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Size Calculation</span></b></p>
<p style="top:97.3pt;left:122.9pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Funding</span></b></p>
<p style="top:728.5pt;left:155.4pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Cooke, 2016</span><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">24</span></p>
<p style="top:658.5pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:586.5pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:522.5pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:454.5pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:377.9pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:298.9pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:230.9pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:170.9pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:97.3pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:728.5pt;left:169.5pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Cooke, 2015</span><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">22</span></p>
<p style="top:658.5pt;left:170.6pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:586.5pt;left:170.6pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:522.5pt;left:170.6pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:454.5pt;left:170.6pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:377.9pt;left:170.6pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:298.9pt;left:170.6pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:230.9pt;left:170.6pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:170.9pt;left:170.6pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:97.3pt;left:170.6pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:728.5pt;left:183.6pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Piasecki, 2015</span><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">23</span></p>
<p style="top:658.5pt;left:184.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:586.5pt;left:184.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:522.5pt;left:184.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:454.5pt;left:184.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:377.9pt;left:184.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:298.9pt;left:184.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:230.9pt;left:184.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:170.9pt;left:184.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:97.3pt;left:184.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:728.5pt;left:197.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Piasecki, 2013</span><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">21</span></p>
<p style="top:658.5pt;left:198.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:586.5pt;left:198.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:522.5pt;left:198.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:454.5pt;left:198.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:377.9pt;left:198.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:298.9pt;left:198.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:230.9pt;left:198.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:170.9pt;left:198.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:97.3pt;left:198.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:728.5pt;left:210.7pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Liu, 2003</span><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">20</span></p>
<p style="top:658.5pt;left:211.8pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:586.5pt;left:211.8pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:522.5pt;left:211.8pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:454.5pt;left:211.8pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:377.9pt;left:211.8pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low risk</span></p>
<p style="top:298.9pt;left:211.8pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:230.9pt;left:211.8pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:170.9pt;left:211.8pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:97.3pt;left:211.8pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:728.1pt;left:358.4pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt;color:#414099">Table 5 </span></b><span style="font-family:Arial,serif;font-size:9.0pt">Risk of bias assessment for clinical studies</span></p>
<p style="top:728.5pt;left:375.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Author, Year</span></b></p>
<p style="top:653.5pt;left:375.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Random </span></b></p>
<p style="top:653.5pt;left:385.4pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Sequence </span></b></p>
<p style="top:653.5pt;left:395.6pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Generation</span></b></p>
<p style="top:578.2pt;left:375.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Allocation </span></b></p>
<p style="top:578.2pt;left:385.4pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Concealment</span></b></p>
<p style="top:515.2pt;left:375.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Blinding of </span></b></p>
<p style="top:515.2pt;left:385.4pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Participants and </span></b></p>
<p style="top:515.2pt;left:395.6pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Personnel</span></b></p>
<p style="top:433.2pt;left:375.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Blinding of </span></b></p>
<p style="top:433.2pt;left:385.4pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Outcome </span></b></p>
<p style="top:433.2pt;left:395.6pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Assessors</span></b></p>
<p style="top:360.2pt;left:375.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Incomplete </span></b></p>
<p style="top:360.2pt;left:385.4pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Outcome Data </span></b></p>
<p style="top:360.2pt;left:395.6pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Addressed</span></b></p>
<p style="top:287.7pt;left:375.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Selective </span></b></p>
<p style="top:287.7pt;left:385.4pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Reporting</span></b></p>
<p style="top:223.7pt;left:375.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Conflicts of </span></b></p>
<p style="top:223.7pt;left:385.4pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Interest</span></b></p>
<p style="top:160.7pt;left:375.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Funding</span></b></p>
<p style="top:99.7pt;left:375.2pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Sample Size </span></b></p>
<p style="top:99.7pt;left:385.4pt;line-height:8.5pt"><b><span style="font-family:Arial,serif;font-size:8.5pt">Calculation</span></b></p>
<p style="top:728.5pt;left:405.0pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Andtbacka, 2015</span><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">13</span><span style="font-family:Arial,serif;font-size:8.5pt"> Low Risk</span></p>
<p style="top:578.2pt;left:408.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:515.2pt;left:408.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:433.2pt;left:408.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:360.2pt;left:408.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:287.7pt;left:408.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:223.7pt;left:408.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:160.7pt;left:408.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:99.7pt;left:408.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:728.5pt;left:421.8pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Long, 2015</span><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">16</span></p>
<p style="top:653.5pt;left:422.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:578.2pt;left:422.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:515.2pt;left:422.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:433.2pt;left:422.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:360.2pt;left:422.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:287.7pt;left:422.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:223.7pt;left:422.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:160.7pt;left:422.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:99.7pt;left:422.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:728.5pt;left:435.9pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Puzanov, 2016</span><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">17</span></p>
<p style="top:653.5pt;left:437.0pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:578.2pt;left:437.0pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:515.2pt;left:437.0pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:433.2pt;left:437.0pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:360.2pt;left:437.0pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:287.7pt;left:437.0pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:223.7pt;left:437.0pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:160.7pt;left:437.0pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:99.7pt;left:437.0pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:728.5pt;left:450.0pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Chang, 2012</span><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">19</span></p>
<p style="top:653.5pt;left:451.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:578.2pt;left:451.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:515.2pt;left:451.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:433.2pt;left:451.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:360.2pt;left:451.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:287.7pt;left:451.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:223.7pt;left:451.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:160.7pt;left:451.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:99.7pt;left:451.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:728.5pt;left:461.3pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Harrington, 2010</span><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">18</span><span style="font-family:Arial,serif;font-size:8.5pt"> High Risk</span></p>
<p style="top:578.2pt;left:465.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:515.2pt;left:465.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:433.2pt;left:465.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:360.2pt;left:465.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:287.7pt;left:465.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:223.7pt;left:465.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:160.7pt;left:465.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:99.7pt;left:465.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:728.5pt;left:478.1pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Senzer, 2009</span><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">15</span></p>
<p style="top:653.5pt;left:479.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:578.2pt;left:479.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:515.2pt;left:479.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:433.2pt;left:479.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:360.2pt;left:479.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:287.7pt;left:479.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:223.7pt;left:479.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:160.7pt;left:479.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:99.7pt;left:479.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:728.5pt;left:491.2pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Hu, 2006</span><span style="font-family:Arial,serif;font-size:5.6pt;color:#0000ff">14</span></p>
<p style="top:653.5pt;left:492.3pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:578.2pt;left:492.3pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:515.2pt;left:492.3pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:433.2pt;left:492.3pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:360.2pt;left:492.3pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Low Risk</span></p>
<p style="top:287.7pt;left:492.3pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:223.7pt;left:492.3pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:160.7pt;left:492.3pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">High Risk</span></p>
<p style="top:99.7pt;left:492.3pt;line-height:8.5pt"><span style="font-family:Arial,serif;font-size:8.5pt">Unclear</span></p>
<p style="top:35.1pt;left:575.3pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">BMJ Open: first published as 10.1136/bmjopen-2019-029475 on 2 December 2019. Downloaded from </span><span style="font-family:Arial,sans-serif;font-size:9.0pt;color:#0000ff">http://bmjopen.bmj.com/</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> on March 2, 2023 by guest. Protected by copyright.</span></p>


<p style="top:758.1pt;left:40.5pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">8</span></b></p>
<p style="top:759.7pt;left:321.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lalu&#xa0;M, </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. </span><i><span style="font-family:Arial,serif;font-size:8.0pt">BMJ Open</span></i><span style="font-family:Arial,serif;font-size:8.0pt"> 2019;</span><b><span style="font-family:Arial,serif;font-size:8.0pt">9</span></b><span style="font-family:Arial,serif;font-size:8.0pt">:e029475. doi:10.1136/bmjopen-2019-029475</span></p>
<p style="top:25.1pt;left:44.3pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#ffffff">Open access </span></b></p>
<p style="top:47.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">all but two clinical studies administered T- VEC to mela-</span></p>
<p style="top:59.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">noma patients. Conversely, lymphoma, which was used </span></p>
<p style="top:71.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">in three preclinical studies, was not assessed in clinical </span></p>
<p style="top:83.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">studies. Interestingly, our subsequent searches found that </span></p>
<p style="top:95.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Amgen&#x2019;s FDA filing (STN# 125518.000)</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">27</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> for T- VEC did </span></p>
<p style="top:107.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">not appear to report on any in vivo melanoma models, </span></p>
<p style="top:119.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">whereas the European Medicines Agency (EMA) report </span></p>
<p style="top:131.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">did (EMA/734400/2015).</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">28</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> Thus, the majority of animal </span></p>
<p style="top:143.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">models were off- target from the malignancies studied in </span></p>
<p style="top:155.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">clinical trials and may have poorly represented melanoma </span></p>
<p style="top:167.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">in the clinical setting. Coupled with these findings was the </span></p>
<p style="top:179.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">fact that the majority of included studies were found to be </span></p>
<p style="top:191.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">at a high or unclear risk of bias for most domains. Such </span></p>
<p style="top:203.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">threats to internal validity can bias results and may help </span></p>
<p style="top:215.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">explain T- VEC&#x2019;s superior preclinical efficacy compared </span></p>
<p style="top:227.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">with later phase clinical trials. A lack of randomisation </span></p>
<p style="top:239.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">and blinding in preclinical studies has been associated </span></p>
<p style="top:251.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">with inflated effect sizes,</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">29 30</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> thus this may partially explain </span></p>
<p style="top:263.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">the preclinical to clinical discrepancy of T- VEC.</span></p>
<p style="top:275.3pt;left:49.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Reporting of methods and findings was incomplete in </span></p>
<p style="top:287.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">most of the studies included. Only one full preclinical </span></p>
<p style="top:299.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">article on T- VEC was published, and solely aggregate </span></p>
<p style="top:311.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">patient data for later phase trials was available. Poor </span></p>
<p style="top:323.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">reporting and study design are major contributors to the </span></p>
<p style="top:335.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ongoing reproducibility crisis in preclinical research.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">31</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> </span></p>
<p style="top:347.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">Thus, in hopes of presenting a clearer picture of T- VEC&#x2019;s </span></p>
<p style="top:359.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">successful translation, we contacted Amgen to obtain </span></p>
<p style="top:371.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">preclinical in vivo melanoma data, patient- level safety </span></p>
<p style="top:383.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">data and any additional efficacy data. Patient- level data </span></p>
<p style="top:395.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">would afford the ability to combine data across T- VEC&#x2019;s </span></p>
<p style="top:407.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">clinical development and also provide clarification into </span></p>
<p style="top:419.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">the categorisation of adverse events. Recently, release of </span></p>
<p style="top:431.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">individual patient data to third parties has been advo-</span></p>
<p style="top:443.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">cated by the Institute of Medicine, journal editors and </span></p>
<p style="top:455.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">others as it enhances transparency, enables reanalyses of </span></p>
<p style="top:467.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">data and helps address reproducibility.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">32</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> The reporting </span></p>
<p style="top:479.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">of harms in clinical trials remains an issue in the scientific </span></p>
<p style="top:491.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">community,</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">33&#x2013;35</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> and represents a roadblock to transla-</span></p>
<p style="top:503.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">tional success. Some basic steps required to improve the </span></p>
<p style="top:515.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">reporting of safety in translational research include the </span></p>
<p style="top:527.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">development of standardised scales and instruments, insti-</span></p>
<p style="top:539.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">tuting active rather than passive surveillance for toxicity, </span></p>
<p style="top:551.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">including detailed information on participant with-</span></p>
<p style="top:563.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">drawals due to toxicity, reporting the timing, frequency </span></p>
<p style="top:575.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">and duration of clinically relevant events and the publi-</span></p>
<p style="top:587.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">cation of raw data.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">36 37</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> Amgen, however</span><i><span style="font-family:NewBaskerville,serif;font-size:10.0pt">,</span></i><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> was unwilling to </span></p>
<p style="top:599.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">enter a data sharing agreement, as they stated that there </span></p>
<p style="top:611.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">was little value to compel a transparent data release for </span></p>
<p style="top:623.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">our proposed analyses. This lack of transparency and </span></p>
<p style="top:635.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">incomplete reporting is disappointing, especially consid-</span></p>
<p style="top:647.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ering that it was Amgen that previously highlighted poor </span></p>
<p style="top:659.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">reporting as contributing to its own failure to reproduce </span></p>
<p style="top:671.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">47 of 53 high- impact preclinical cancer studies.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">38</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> Their </span></p>
<p style="top:683.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">findings fuelled a call by the National Institutes of Health </span></p>
<p style="top:695.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">(NIH) and other stakeholders to enhance the reproduc-</span></p>
<p style="top:707.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ibility and transparency of preclinical research.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">39</span></sup></p>
<p style="top:719.3pt;left:49.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">As stated, we recognise that translation is not a linear </span></p>
<p style="top:731.3pt;left:40.5pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">process, but we should observe consistent and coherent </span></p>
<p style="top:47.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">patterns. Moving forward, we suggest that preclinical and </span></p>
<p style="top:59.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">clinical studies for emerging therapies should be fully </span></p>
<p style="top:71.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">reported and attention should be given to validities in </span></p>
<p style="top:83.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">order to develop more precise estimates of effect early </span></p>
<p style="top:95.6pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">in development. Investigators should carefully match </span></p>
<p style="top:107.6pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">their preclinical model to the intended clinical popu-</span></p>
<p style="top:119.7pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">lation; when possible, both disease states and outcomes </span></p>
<p style="top:131.7pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">measured should have high construct validity. Following </span></p>
<p style="top:143.8pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">successful exploratory preclinical studies, investigators </span></p>
<p style="top:155.9pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">should consider preclinical systematic reviews</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">40</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> and </span></p>
<p style="top:167.9pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">designing methodologically rigorous confirmatory and/</span></p>
<p style="top:180.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">or multicentre preclinical studies.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">41</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> These steps may allow </span></p>
<p style="top:192.0pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">preclinical testing to more accurately forecast downstream </span></p>
<p style="top:204.1pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">clinical results in human patients.</span><sup><span style="font-family:NewBaskerville,serif;font-size:6.6pt;color:#0000ff">30</span></sup><span style="font-family:NewBaskerville,serif;font-size:10.0pt"> Within the trajectory </span></p>
<p style="top:216.2pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">of clinical development (ie, once clinical trials have been </span></p>
<p style="top:228.2pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">initiated), careful consideration of methods to reduce </span></p>
<p style="top:240.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">bias should also be considered (although, this may not </span></p>
<p style="top:252.3pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">be possible for the earliest phase trials). We believe these </span></p>
<p style="top:264.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">steps will provide unbiased and valuable information that </span></p>
<p style="top:276.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">will ultimately provide patients with cancer therapies that </span></p>
<p style="top:288.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">match their preclinical and early clinical promise.</span></p>
<p style="top:331.3pt;left:306.9pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">COnCLusIOns</span></b></p>
<p style="top:343.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">The findings from our systematic review demonstrate that </span></p>
<p style="top:355.4pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">even successful biotherapeutics may not demonstrate a </span></p>
<p style="top:367.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">clear translational road map. The magnitude of efficacy of </span></p>
<p style="top:379.5pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">T- VEC demonstrated in preclinical studies was considerably </span></p>
<p style="top:391.6pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">larger than subsequent clinical trials; the most methodolog-</span></p>
<p style="top:403.7pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">ically rigorous trial included in our review demonstrated </span></p>
<p style="top:415.7pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">the smallest degree of efficacy. Methodologically rigorous </span></p>
<p style="top:427.8pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">studies should be performed earlier on in the translational </span></p>
<p style="top:439.8pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">pathway, which may help provide a realistic estimate of </span></p>
<p style="top:451.9pt;left:306.9pt;line-height:10.0pt"><span style="font-family:NewBaskerville,serif;font-size:10.0pt">treatment efficacy prior to clinical translation.</span></p>
<p style="top:475.6pt;left:306.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099">Author affiliations</span></b></p>
<p style="top:484.2pt;left:306.9pt;line-height:5.3pt"><span style="font-family:Arial,serif;font-size:5.3pt">1</span><span style="font-family:Arial,serif;font-size:8.0pt">BLUEPRINT Translational Research Group, Clinical Epidemiology Program, Ottawa </span></p>
<p style="top:495.7pt;left:306.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Hospital Research Institute, Ottawa, Ontario, Canada</span></p>
<p style="top:504.3pt;left:306.9pt;line-height:5.3pt"><span style="font-family:Arial,serif;font-size:5.3pt">2</span><span style="font-family:Arial,serif;font-size:8.0pt">Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, Ottawa, </span></p>
<p style="top:515.8pt;left:306.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Ontario, Canada</span></p>
<p style="top:524.4pt;left:306.9pt;line-height:5.3pt"><span style="font-family:Arial,serif;font-size:5.3pt">3</span><span style="font-family:Arial,serif;font-size:8.0pt">Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, </span></p>
<p style="top:535.9pt;left:306.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Ontario, Canada</span></p>
<p style="top:544.5pt;left:306.9pt;line-height:5.3pt"><span style="font-family:Arial,serif;font-size:5.3pt">4</span><span style="font-family:Arial,serif;font-size:8.0pt">Department of Cellular and Molecular Medicine, Ottawa Hospital Research </span></p>
<p style="top:556.0pt;left:306.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Institute, Ottawa, Ontario, Canada</span></p>
<p style="top:564.7pt;left:306.9pt;line-height:5.3pt"><span style="font-family:Arial,serif;font-size:5.3pt">5</span><span style="font-family:Arial,serif;font-size:8.0pt">Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada</span></p>
<p style="top:574.7pt;left:306.9pt;line-height:5.3pt"><span style="font-family:Arial,serif;font-size:5.3pt">6</span><span style="font-family:Arial,serif;font-size:8.0pt">Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada</span></p>
<p style="top:584.8pt;left:306.9pt;line-height:5.3pt"><span style="font-family:Arial,serif;font-size:5.3pt">7</span><span style="font-family:Arial,serif;font-size:8.0pt">Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, </span></p>
<p style="top:596.3pt;left:306.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Canada</span></p>
<p style="top:604.9pt;left:306.9pt;line-height:5.3pt"><span style="font-family:Arial,serif;font-size:5.3pt">8</span><span style="font-family:Arial,serif;font-size:8.0pt">School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, </span></p>
<p style="top:616.4pt;left:306.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Canada</span></p>
<p style="top:638.5pt;left:306.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099">twitter </span></b><span style="font-family:Arial,serif;font-size:8.0pt">Manoj Lalu @manojlalu</span></p>
<p style="top:652.1pt;left:306.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099">Acknowledgements </span></b><span style="font-family:Arial,serif;font-size:8.0pt">The authors thank Risa Shorr (Ottawa Hospital Research </span></p>
<p style="top:661.8pt;left:306.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Institute librarian) for systematic search assistance. ML is supported by The Ottawa </span></p>
<p style="top:671.4pt;left:306.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Hospital Anesthesia Alternate Funds Association and the Scholarship Protected Time </span></p>
<p style="top:681.1pt;left:306.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Program, Department of Anesthesiology and Pain Medicine, Ottawa.</span></p>
<p style="top:694.7pt;left:306.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099">Contributors </span></b><span style="font-family:Arial,serif;font-size:8.0pt">ML and DAF conceptualised the study. ML, RCA, DAF and GJL </span></p>
<p style="top:704.3pt;left:306.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">contributed to the study design. GJL, YYD, JM and CB conducted data extraction. </span></p>
<p style="top:713.9pt;left:306.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">All authors analysed and interpreted the data. ML and GJL were responsible for </span></p>
<p style="top:723.5pt;left:306.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">drafting the manuscript. All authors critically reviewed the manuscript and provided </span></p>
<p style="top:733.1pt;left:306.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">intellectual content. All authors approve the final version of the manuscript.</span></p>
<p style="top:35.1pt;left:575.3pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">BMJ Open: first published as 10.1136/bmjopen-2019-029475 on 2 December 2019. Downloaded from </span><span style="font-family:Arial,sans-serif;font-size:9.0pt;color:#0000ff">http://bmjopen.bmj.com/</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> on March 2, 2023 by guest. Protected by copyright.</span></p>


<p style="top:758.1pt;left:550.1pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">9</span></b></p>
<p style="top:759.7pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lalu&#xa0;M, </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. </span><i><span style="font-family:Arial,serif;font-size:8.0pt">BMJ Open</span></i><span style="font-family:Arial,serif;font-size:8.0pt"> 2019;</span><b><span style="font-family:Arial,serif;font-size:8.0pt">9</span></b><span style="font-family:Arial,serif;font-size:8.0pt">:e029475. doi:10.1136/bmjopen-2019-029475</span></p>
<p style="top:25.1pt;left:482.6pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#ffffff">Open access</span></b></p>
<p style="top:47.8pt;left:40.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099">Funding </span></b><span style="font-family:Arial,serif;font-size:8.0pt">Biotherapeutics for Cancer Treatment (BioCanRx) supported the conduct </span></p>
<p style="top:57.4pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">of this study by a Catalyst grant. BioCanRx is a Government of Canada funded </span></p>
<p style="top:67.0pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Networks of Centres of Excellence and was not involved in any other aspect of the </span></p>
<p style="top:76.6pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">project, such as the design of the project&#x2019;s protocol and analysis plan, the collection </span></p>
<p style="top:86.2pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">of data and analyses. CB was also supported by a BioCanRx studentship. ML is </span></p>
<p style="top:95.8pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">supported by The Ottawa Hospital Anesthesia Alternate Funds Association and </span></p>
<p style="top:105.4pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">the Scholarship Protected Time Program, Department of Anesthesiology and Pain </span></p>
<p style="top:115.0pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Medicine, uOttawa.</span></p>
<p style="top:128.6pt;left:40.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099">Competing interests </span></b><span style="font-family:Arial,serif;font-size:8.0pt">None declared.</span></p>
<p style="top:142.6pt;left:40.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099">Patient consent for publication </span></b><span style="font-family:Arial,serif;font-size:8.0pt">Not required.</span></p>
<p style="top:156.2pt;left:40.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099">Provenance and peer review </span></b><span style="font-family:Arial,serif;font-size:8.0pt">Not commissioned; externally peer reviewed.</span></p>
<p style="top:169.8pt;left:40.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099">Data availability statement </span></b><span style="font-family:Arial,serif;font-size:8.0pt">All data relevant to the study are included in the </span></p>
<p style="top:179.4pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">article or uploaded as supplementary information.</span></p>
<p style="top:193.0pt;left:40.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099">Open access </span></b><span style="font-family:Arial,serif;font-size:8.0pt">This is an open access article distributed in accordance with the </span></p>
<p style="top:202.6pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which </span></p>
<p style="top:212.2pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">permits others to distribute, remix, adapt, build upon this work non- commercially, </span></p>
<p style="top:221.8pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">and license their derivative works on different terms, provided the original work is </span></p>
<p style="top:231.4pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">properly cited, appropriate credit is given, any changes made indicated, and the use </span></p>
<p style="top:241.0pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">is non- commercial. See:&#xa0;http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.</span></p>
<p style="top:258.6pt;left:40.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt;color:#414099">OrCID iD</span></b></p>
<p style="top:268.2pt;left:40.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Manoj&#xa0;Lalu </span><span style="font-family:Arial,serif;font-size:8.0pt;color:#0000ff">http:// orcid. org/ 0000- 0002- 0322- 382X</span></p>
<p style="top:304.6pt;left:40.5pt;line-height:10.0pt"><b><span style="font-family:Arial,serif;font-size:10.0pt;color:#414099">rEFErEnCEs</span></b></p>
<p style="top:315.1pt;left:40.5pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 1 Freedman LP, Cockburn IM, Simcoe TS. The economics of </span></p>
<p style="top:323.6pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">reproducibility in preclinical research. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">PLoS Biol</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2015;13:e1002165.</span></p>
<p style="top:332.1pt;left:40.5pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 2 Contopoulos- Ioannidis DG, Ntzani EE, Ioannidis JPA. Translation of </span></p>
<p style="top:340.6pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">highly promising basic science research into clinical applications. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Am </span></i></p>
<p style="top:349.1pt;left:56.4pt;line-height:7.5pt"><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">J Med</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2003;114:477&#x2013;84.</span></p>
<p style="top:357.6pt;left:40.5pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 3 Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the </span></p>
<p style="top:366.1pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">question: understanding time lags in translational research. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">J R Soc </span></i></p>
<p style="top:374.6pt;left:56.4pt;line-height:7.5pt"><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Med</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2011;104:510&#x2013;20.</span></p>
<p style="top:383.1pt;left:40.5pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 4 </span><i><span style="font-family:Arial,serif;font-size:7.5pt">Use of laboratory animals in biomedical and behavioral research</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. </span></p>
<p style="top:391.6pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">Washington (DC), 1988.</span></p>
<p style="top:400.1pt;left:40.5pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 5 Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical </span></p>
<p style="top:408.6pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">trials: a narrative review. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Postgrad Med</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2011;123:194&#x2013;204.</span></p>
<p style="top:417.1pt;left:40.5pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 6 Rehman H, Silk AW, Kane MP, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Into the clinic: Talimogene </span></p>
<p style="top:425.6pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">laherparepvec (T- VEC), a first- in- class intratumoral oncolytic viral </span></p>
<p style="top:434.1pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">therapy. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">J Immunother Cancer</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2016;4.</span></p>
<p style="top:442.6pt;left:40.5pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 7 Fergusson DA, Wesch NL, Leung GJ, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Assessing the </span></p>
<p style="top:451.1pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">completeness of reporting in preclinical oncolytic virus therapy </span></p>
<p style="top:459.6pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">studies. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Molecular Therapy - Oncolytics</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2019;14:179&#x2013;87.</span></p>
<p style="top:468.1pt;left:40.5pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 8 Moher D, Liberati A, Tetzlaff J, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Preferred reporting items for </span></p>
<p style="top:476.6pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">systematic reviews and meta- analyses: the PRISMA statement. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">J </span></i></p>
<p style="top:485.1pt;left:56.4pt;line-height:7.5pt"><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Clin Epidemiol</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2009;62:1006&#x2013;12.</span></p>
<p style="top:493.6pt;left:40.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 9 Eisenhauer EA, Therasse P, Bogaerts J, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. New response </span></p>
<p style="top:502.1pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">evaluation criteria in solid tumours: revised RECIST guideline (version </span></p>
<p style="top:510.6pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">1.1). </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Eur J Cancer</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2009;45:228&#x2013;47.</span></p>
<p style="top:519.1pt;left:40.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 10 Higgins JPT, Altman DG, Gotzsche PC, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. The Cochrane </span></p>
<p style="top:527.5pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">collaboration&apos;s tool for assessing risk of bias in randomised trials. </span></p>
<p style="top:536.0pt;left:56.4pt;line-height:7.5pt"><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">BMJ</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2011;343:d5928.</span></p>
<p style="top:544.5pt;left:40.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 11 Hooijmans CR, Rovers MM, de Vries RBM, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. SYRCLE&apos;s risk of </span></p>
<p style="top:553.0pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">bias tool for animal studies. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">BMC Med Res Methodol</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2014;14:43.</span></p>
<p style="top:561.5pt;left:40.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 12 Newcombe RG. Two- Sided confidence intervals for the </span></p>
<p style="top:570.0pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">single proportion: comparison of seven methods. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Stat Med</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> </span></p>
<p style="top:578.5pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">1998;17:857&#x2013;72.</span></p>
<p style="top:587.0pt;left:40.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 13 Andtbacka RHI, Kaufman HL, Collichio F, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Talimogene </span></p>
<p style="top:595.5pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">Laherparepvec improves durable response rate in patients with </span></p>
<p style="top:604.0pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">advanced melanoma. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">JCO</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2015;33:2780&#x2013;8.</span></p>
<p style="top:612.5pt;left:40.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 14 Hu JCC, Coffin RS, Davis CJ, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. A phase I study of OncoVEXGM- </span></p>
<p style="top:621.0pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">CSF, a second- generation oncolytic herpes simplex virus expressing </span></p>
<p style="top:629.5pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">granulocyte macrophage colony- stimulating factor. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Clin Cancer Res</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> </span></p>
<p style="top:638.0pt;left:56.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">2006;12:6737&#x2013;47.</span></p>
<p style="top:646.5pt;left:40.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 15 Senzer NN, Kaufman HL, Amatruda T, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Phase II clinical </span></p>
<p style="top:655.0pt;left:56.3pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">trial of a granulocyte- macrophage colony- stimulating Factor&#x2013;</span></p>
<p style="top:663.5pt;left:56.3pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">Encoding, second- generation oncolytic herpesvirus in patients with </span></p>
<p style="top:672.0pt;left:56.3pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">unresectable metastatic melanoma. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">JCO</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2009;27:5763&#x2013;71.</span></p>
<p style="top:680.5pt;left:40.4pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 16 Long GV, Dummer R, Ribas A, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. 24LBA safety data from the </span></p>
<p style="top:689.0pt;left:56.3pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">phase 1B part of the MASTERKEY-265 study combining talimogene </span></p>
<p style="top:697.5pt;left:56.3pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">laherparepvec (T- VEC) and pembrolizumab for unresectable stage </span></p>
<p style="top:706.0pt;left:56.3pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">IIIB- IV melanoma. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Eur J Cancer</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2015;51:S722.</span></p>
<p style="top:47.7pt;left:306.8pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 17 Puzanov I, Milhem MM, Minor D, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Talimogene Laherparepvec in </span></p>
<p style="top:56.3pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">combination with ipilimumab in previously untreated, unresectable </span></p>
<p style="top:64.8pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">stage IIIB- IV melanoma. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">JCO</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2016;34:2619&#x2013;26.</span></p>
<p style="top:73.4pt;left:306.8pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 18 Harrington KJ, Hingorani M, Tanay MA, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Phase I/II study of </span></p>
<p style="top:81.9pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">oncolytic HSVGM- CSF in combination with radiotherapy and </span></p>
<p style="top:90.4pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">cisplatin in untreated stage III/IV squamous cell cancer of the head </span></p>
<p style="top:99.0pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">and neck. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Clinical Cancer Research</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2010;16:4005&#x2013;15.</span></p>
<p style="top:107.5pt;left:306.8pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 19 Chang KJ, Senzer NN, Binmoeller K, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Phase I dose- escalation </span></p>
<p style="top:116.1pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">study of talimogene laherparepvec (T- VEC) for advanced pancreatic </span></p>
<p style="top:124.6pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">cancer (Ca). </span><i><span style="font-family:Arial,serif;font-size:7.5pt">Journal of Clinical Oncology</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2012;30.</span></p>
<p style="top:133.2pt;left:306.8pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 20 Liu BL, Robinson M, Han Z- Q, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Icp34.5 deleted herpes simplex </span></p>
<p style="top:141.7pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">virus with enhanced oncolytic, immune stimulating, and anti- tumour </span></p>
<p style="top:150.2pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">properties. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Gene Ther</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2003;10:292&#x2013;303.</span></p>
<p style="top:158.8pt;left:306.8pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 21 Piasecki J, Tiep L, Zhou J, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Talilmogene Iaherparepvec </span></p>
<p style="top:167.3pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">generates systemic T- cell- mediated anti- tumor immunity. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">J </span></i></p>
<p style="top:175.9pt;left:322.7pt;line-height:7.5pt"><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Immunother Cancer</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2013;1.</span></p>
<p style="top:184.4pt;left:306.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 22 Cooke K, Rottman J, Zhan J, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Oncovex MGM- CSF &#x2013;mediated </span></p>
<p style="top:193.0pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">regression of contralateral (non- injected) tumors in the A20 </span></p>
<p style="top:201.5pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">murine lymphoma model does not involve direct viral oncolysis. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">J </span></i></p>
<p style="top:210.0pt;left:322.7pt;line-height:7.5pt"><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Immunother Cancer</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2015;3.</span></p>
<p style="top:218.6pt;left:306.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 23 Piasecki J, le T, Ponce R, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Abstract 258: Talilmogene </span></p>
<p style="top:227.1pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">laherparepvec increases the anti- tumor efficacy of the anti- PD-1 </span></p>
<p style="top:235.7pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">immune checkpoint blockade. </span><i><span style="font-family:Arial,serif;font-size:7.5pt">Cancer Research</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2015;75:258.</span></p>
<p style="top:244.2pt;left:306.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 24 Cooke K, Estrada J, Zhan J, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Abstract 2351: development </span></p>
<p style="top:252.8pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">of a B16F10 cell line expressing mNectin1 to study the activity of </span></p>
<p style="top:261.3pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">OncoVEXmGM- CSF in murine syngeneic melanoma models. </span><i><span style="font-family:Arial,serif;font-size:7.5pt">Cancer </span></i></p>
<p style="top:269.8pt;left:322.7pt;line-height:7.5pt"><i><span style="font-family:Arial,serif;font-size:7.5pt">Research</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2016;76:2351.</span></p>
<p style="top:278.4pt;left:306.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 25 Louie RJ, Perez MC, Jajja MR, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Real- World outcomes of </span></p>
<p style="top:286.9pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">Talimogene Laherparepvec therapy: a multi- institutional experience. </span></p>
<p style="top:295.5pt;left:322.7pt;line-height:7.5pt"><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">J Am Coll Surg</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2019;228:644&#x2013;9.</span></p>
<p style="top:304.0pt;left:306.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 26 National Comprehensive Cancer Center. Guidelines for patients: </span></p>
<p style="top:312.6pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">melanoma 2018.</span></p>
<p style="top:321.1pt;left:306.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 27 US Food and Drug Administration. IMLYGIC (talimogene </span></p>
<p style="top:329.6pt;left:322.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">laherparepvec), 2015. Available: https://www. fda. gov/ vaccines- </span></p>
<p style="top:338.2pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">blood- biologics/ cellular- gene- therapy- products/ imlygic- talimogene- </span></p>
<p style="top:346.7pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">laherparepvec</span></p>
<p style="top:355.3pt;left:306.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 28 European Medicines Agency. Assessment report Imlygic international </span></p>
<p style="top:363.8pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">non- proprietary name: talimogene laherparepvec, 2015. Available: </span></p>
<p style="top:372.4pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">https://www. ema. europa. eu/ en/ documents/ assessment- report/ </span></p>
<p style="top:380.9pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">imlygic- epar- public- assessment- report_ en. pdf</span></p>
<p style="top:389.4pt;left:306.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 29 Hirst JA, Howick J, Aronson JK, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. The need for randomization </span></p>
<p style="top:398.0pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">in animal trials: an overview of systematic reviews. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">PLoS One</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> </span></p>
<p style="top:406.5pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">2014;9:e98856.</span></p>
<p style="top:415.1pt;left:306.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 30 Macleod MR, van der Worp HB, Sena ES, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Evidence for the </span></p>
<p style="top:423.6pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">efficacy of NXY-059 in experimental focal cerebral ischaemia is </span></p>
<p style="top:432.1pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">confounded by study quality. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Stroke</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2008;39:2824&#x2013;9.</span></p>
<p style="top:440.7pt;left:306.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 31 Landis SC, Amara SG, Asadullah K, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. A call for transparent </span></p>
<p style="top:449.2pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">reporting to optimize the predictive value of preclinical research. </span></p>
<p style="top:457.8pt;left:322.6pt;line-height:7.5pt"><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Nature</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2012;490:187&#x2013;91.</span></p>
<p style="top:466.3pt;left:306.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 32 Zarin DA, Tse T. Sharing individual participant data (IPD) within </span></p>
<p style="top:474.9pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">the context of the trial reporting system (TRS). </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">PLoS Med</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> </span></p>
<p style="top:483.4pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">2016;13:e1001946.</span></p>
<p style="top:491.9pt;left:306.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 33 Hodkinson A, Kirkham JJ, Tudur- Smith C, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Reporting </span></p>
<p style="top:500.5pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">of harms data in RCTs: a systematic review of empirical </span></p>
<p style="top:509.0pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">assessments against the CONSORT harms extension. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">BMJ Open</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> </span></p>
<p style="top:517.6pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">2013;3:e003436.</span></p>
<p style="top:526.1pt;left:306.7pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 34 Rodgers MA, Brown JVE, Heirs MK, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Reporting of industry </span></p>
<p style="top:534.7pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">funded study outcome data: comparison of confidential and </span></p>
<p style="top:543.2pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">published data on the safety and effectiveness of rhBMP-2 for spinal </span></p>
<p style="top:551.7pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">fusion. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">BMJ</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2013;346:f3981.</span></p>
<p style="top:560.3pt;left:306.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 35 Jureidini JN, McHenry LB, Mansfield PR. Clinical trials and drug </span></p>
<p style="top:568.8pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">promotion: selective reporting of study 329. </span><i><span style="font-family:Arial,serif;font-size:7.5pt">International Journal of </span></i></p>
<p style="top:577.4pt;left:322.6pt;line-height:7.5pt"><i><span style="font-family:Arial,serif;font-size:7.5pt">Risk &amp; Safety in Medicine</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2008;20:73&#x2013;81.</span></p>
<p style="top:585.9pt;left:306.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 36 Ioannidis JPA, Lau J. Improving safety reporting from randomised </span></p>
<p style="top:594.5pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">trials. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Drug Safety</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2002;25:77&#x2013;84.</span></p>
<p style="top:603.0pt;left:306.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 37 Lineberry N, Berlin JA, Mansi B, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Recommendations to </span></p>
<p style="top:611.5pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">improve adverse event reporting in clinical trial publications: a joint </span></p>
<p style="top:620.1pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">pharmaceutical industry/journal editor perspective. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">BMJ</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2016;355.</span></p>
<p style="top:628.6pt;left:306.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 38 Begley CG, Ellis LM. Drug development: raise standards for </span></p>
<p style="top:637.2pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">preclinical cancer research. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Nature</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2012;483:531&#x2013;3.</span></p>
<p style="top:645.7pt;left:306.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 39 Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility. </span></p>
<p style="top:654.3pt;left:322.6pt;line-height:7.5pt"><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Nature</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2014;505:612&#x2013;3.</span></p>
<p style="top:662.8pt;left:306.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 40 Lalu MM, Sullivan KJ, Mei SHJ, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Evaluating mesenchymal </span></p>
<p style="top:671.3pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">stem cell therapy for sepsis with preclinical meta- analyses prior to </span></p>
<p style="top:679.9pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">initiating a first- in- human trial. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">eLife</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2016;5.</span></p>
<p style="top:688.4pt;left:306.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt"> 41 Llovera G, Hofmann K, Roth S, </span><i><span style="font-family:Arial,serif;font-size:7.5pt">et&#xa0;al</span></i><span style="font-family:Arial,serif;font-size:7.5pt">. Results of a preclinical </span></p>
<p style="top:697.0pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">randomized controlled multicenter trial (pRCT): Anti- CD49d treatment </span></p>
<p style="top:705.5pt;left:322.6pt;line-height:7.5pt"><span style="font-family:Arial,serif;font-size:7.5pt">for acute brain ischemia. </span><i><span style="font-family:Arial,serif;font-size:7.5pt;color:#0000ff">Sci Transl Med</span></i><span style="font-family:Arial,serif;font-size:7.5pt"> 2015;7:ra121.</span></p>
<p style="top:35.1pt;left:575.3pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">BMJ Open: first published as 10.1136/bmjopen-2019-029475 on 2 December 2019. Downloaded from </span><span style="font-family:Arial,sans-serif;font-size:9.0pt;color:#0000ff">http://bmjopen.bmj.com/</span><span style="font-family:Arial,sans-serif;font-size:9.0pt"> on March 2, 2023 by guest. Protected by copyright.</span></p>

</div>
